FGF-21 as a novel metabolic regulator.
paper
Cited
Public
Unavailable
- Authors
- Kharitonenkov, Alexei; Shiyanova, Tatiyana L; Koester, Anja; Ford, Amy M; Micanovic, Radmila; Galbreath, Elizabeth J; Sandusky, George E; Hammond, Lisa J; Moyers, Julie S; Owens, Rebecca A; Gromada, Jesper; Brozinick, Joseph T; Hawkins, Eric D; Wroblewski, Victor J; Li, De-Shan; Mehrbod, Farrokh; Jaskunas, S Richard; Shanafelt, Armen B
- Year
- 2005
- Journal
- The Journal of clinical investigation
- PMID
- 15902306
- DOI
- 10.1172/JCI23606
- PMCID
- PMC1088017
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Adissp activates insulin-independent glucose disposal and energy expenditure in white fat to treat diabetes and cardiometabolic disease. | Huang L et al. | β | 2026 | β |
| Advancements in understanding the role and mechanisms of mitochondria in diabetes: A comprehensive review. | Ge X et al. | β | 2026 | β |
| Clinical and metabolic benefits of efruxifermin in MASH: a GRADE-assessed meta-analysis of randomized trials with trial sequential analysis. | Rajab I et al. | β | 2026 | β |
| Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF-21), and insulin-like growth factor binding protein 2 (IGFBP-2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrum. | Dallaire-ThΓ©roux C et al. | β | 2026 | β |
| Efficiency of afamin and fibroblast growth factor 21 for early prediction of gestational diabetes mellitus. | Sabri AO et al. | β | 2026 | β |
| Evaluation methods of hepatic steatosis: From conventional techniques to emerging biomarkers. | Moriyama K | β | 2026 | β |
| Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels. | Luther J et al. | β | 2026 | β |
| Functions of FGF21 and its role in cardiac hypertrophy. | Chen L et al. | β | 2026 | β |
| International Utah cardiac recovery symposium (U-CARS) 2025:translational and basic science proceedings. | Visker JR et al. | β | 2026 | β |
| Interorgan crosstalk in metabolic dysfunction-associated steatotic liver disease. | Yang R et al. | β | 2026 | β |
| New Mechanistic Evidence for Perfluorodecanoic Acid (PFDA) Teratogenicity via CYP26A1-Mediated Retinoic Acid Metabolism and Signaling. | Hvizdak M et al. | β | 2026 | β |
| NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice. | Bultinck J et al. | β | 2026 | β |
| Osthole Activates FGF21 Expression by Mediating Activation of ATF4 in Human Hepatocyte HepG2 Cells. | Taguchi A et al. | β | 2026 | β |
| Pachymic Acid Alleviates Non-Alcoholic Fatty Liver Disease via FGF21-Mediated Inhibition of the p38 MAPK Pathway. | Nie L et al. | β | 2026 | β |
| Pharmacological administration of FGF21 reverses obesity through a parabrachial-projecting neuron population in the hindbrain. | Lin Y et al. | β | 2026 | β |
| Reexamining Fat: Exploring Diversity, Plasticity, Development, Functional Implication, and Therapeutic Options. | Dowker-Key PD et al. | β | 2026 | β |
| Research progress on the role and mechanism of traditional Chinese medicine based on "liver-multiple-organ interaction". | Yang C et al. | β | 2026 | β |
| Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency. | Volkert I et al. | β | 2026 | β |
| The burn repair molecule? Evaluating FGF-21 in thermal injury - A systematic review. | Niederegger T et al. | β | 2026 | β |
| The role of fibroblast growth factors in cell and cancerΒ metabolism. | Price J et al. | β | 2026 | β |
| ADAM10-mediated Ξ²-klotho degradation: a key to FGF21 resistance in senescent vascular endothelial cells. | Huang Y et al. | β | 2025 | β |
| Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions. | Besci O et al. | β | 2025 | β |
| A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control. | Du P et al. | β | 2025 | β |
| A systematic review and meta-analysis of efruxifermin's efficacy in improving liver fibrosis in patients with NASH/MASH. | Li S et al. | β | 2025 | β |
| A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics. | Rao Z et al. | β | 2025 | β |
| Brain-acting hepatokines: its impact on energy balance and metabolism. | Giovanini L et al. | β | 2025 | β |
| Brain amino acid sensing for organismal amino acid homeostasis. | Tsang AH et al. | β | 2025 | β |
| Branched-chain amino acids promote hepatic Cyp7a1 expression and bile acid synthesis via suppressing FGF21-ERK pathway. | Wang J et al. | β | 2025 | β |
| Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective. | Tuokkola JE et al. | β | 2025 | β |
| Cgref1 is a CREB-H-regulated hepatokine that promotes hepatic <i>de novo</i> lipogenesis by mediating epididymal fat insulin resistance. | Chan P et al. | β | 2025 | β |
| Circulating fibroblast growth factor 21 levels in gestational diabetes mellitus and preeclampsia: a systematic review and meta-analysis. | Cao Z et al. | β | 2025 | β |
| Circulating mitokines GDF-15 and FGF21 are associated with frailty, sarcopenia, and malnutrition in older adults: Evidence from the FRASNET study. | Damanti S et al. | β | 2025 | β |
| Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH. | Raji A et al. | β | 2025 | β |
| Combination of Berberine and Evodiamine Alleviates Obesity by Promoting Browning in 3T3-L1 Cells and High-Fat Diet-Induced Mice. | Zhang H et al. | β | 2025 | β |
| Development of FGF21 Mutant with Potent Cardioprotective Effects in T2D Mice via FGFR1-AMPK-Mediated Inhibition of Oxidative Stress. | Peng Z et al. | β | 2025 | β |
| Dietary Insulinogenic Amino Acid Restriction Improves Glucose Metabolism in a Neonatal Piglet Model. | Gorton MW et al. | β | 2025 | β |
| Dietary protein restriction elevates FGF21 levels and energy requirements to maintain body weight in lean men. | Nicolaisen TS et al. | β | 2025 | β |
| Dysregulation of the FGF21-Adiponectin Axis in a Large Cohort of Patients with Severe Obesity and Liver Disease. | CastaΓ±Γ© H et al. | β | 2025 | β |
| Effect of exercise on Fibroblast Growth Factor 21 levels in healthy males and females. | Peterson M et al. | β | 2025 | β |
| Effects and Safety of FGF21 Analogs on Glycemic Parameters, Lipid Profiles, and Adiponectin in Overweight and Obese Adults: A Meta-Analysis of Randomized Controlled Trials. | Nie Z et al. | β | 2025 | β |
| Effects of FGF21, soluble TGFBR2, and environmental temperature on metabolic dysfunction in lipodystrophic mice. | Maung JN et al. | β | 2025 | β |
| Effects of fibroblast growth factor 21 serum level on clinicopathological findings in papillary thyroid carcinoma. | Mosalamiaghili S et al. | β | 2025 | β |
| Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial. | Ozlu Karahan T et al. | β | 2025 | β |
| Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. | Dolovitsch de Oliveira F et al. | β | 2025 | β |
| Emerging Biomarkers and Nanobiosensing Strategies in Diabetes. | Baranwal A et al. | β | 2025 | β |
| Emerging in Diabetic Cardiomyopathy: Molecular Pathways and Targets for Therapeutic Intervention. | Trivedi MV et al. | β | 2025 | β |
| Emerging Technologies and Future Directions in Interorgan Crosstalk Cardiometabolic Research. | Bae H et al. | β | 2025 | β |
| Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article. | Mehdi SF et al. | β | 2025 | β |
| Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer. | Karin M et al. | β | 2025 | β |
| Ethyl Lactate Ameliorates Hepatic Steatosis and Acute-on-Chronic Liver Injury in Alcohol-Associated Liver Disease by Inducing Fibroblast Growth Factor 21. | Jiang Y et al. | β | 2025 | β |
| FGF21 and the brain-liver axis: Harnessing sympathetic pathways in MASH. | Marjot T | β | 2025 | β |
| FGF21 keeps the thymus young. | Takahama Y | β | 2025 | β |
| FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice. | Zhang K et al. | β | 2025 | β |
| FGF-based drug discovery: advances and challenges. | Chen G et al. | β | 2025 | β |
| Fibroblast growth factor 21 affects the colocalization of post-synaptic density 95 and Kalirin7 through CYLD-expression regulation. | Yoshida Y et al. | β | 2025 | β |
| Fibroblast Growth Factor 21 Protects Against Cerebral Ischemia/Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis. | Li J et al. | β | 2025 | β |
| Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion. | Tuokkola JE et al. | β | 2025 | β |
| Fibroblast Growth Factors: Roles and Emerging Therapeutic Applications. | Ternier G et al. | β | 2025 | β |
| Hepato-cardiac interorgan communication controls cardiac hypertrophy via combined endocrine-autocrine FGF21 signaling. | Mia S et al. | β | 2025 | β |
| Increased thermal stability of FGF10 leads to ectopic signaling during development. | Czyrek AA et al. | β | 2025 | β |
| Insulin resistance in type 2 diabetes mellitus. | Accili D et al. | β | 2025 | β |
| International Symposium on Ruminant Physiology: Endocrine adaptations to demanding physiological states in ruminants. | Boisclair YR et al. | β | 2025 | β |
| Intranasal administration of mesenchymal stem cells overexpressing FGF21 demonstrates therapeutic potential in experimental Parkinson's disease. | Lin YY et al. | β | 2025 | β |
| Investigation of the protective effects of dichloroacetic acid in a rat model of diabetic neuropathy. | ArΔ± M et al. | β | 2025 | β |
| Mammalian mitohormesis: from mitochondrial stressors to organismal benefits. | Gunawan AL et al. | β | 2025 | β |
| Manipulating dietary protein and amino acids in the common marmoset Callithrix jacchus impacts circulating metabolites and FGF21 levels. | Fujita Y et al. | β | 2025 | β |
| Metabolomics-Guided Genomic Comparisons Reveal Convergent Evolution of Hibernation Genes in Mammals. | Drabeck DH et al. | β | 2025 | β |
| Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases. | Rojo AI et al. | β | 2025 | β |
| Muscle cells affect the promoting effect of FGF21 on lipid accumulation in porcine adipocytes through AhR/FGFR1 signaling pathway. | Qiu S et al. | β | 2025 | β |
| Myokines and interorgan crosstalk: bridging exercise to health promotion and disease prevention. | Ha J et al. | β | 2025 | β |
| Obesity and Exercise: New Insights and Perspectives. | James NM et al. | β | 2025 | β |
| Overexpression and biophysical and functional characterization of a recombinant FGF21. | Phan P et al. | β | 2025 | β |
| p38Ξ± MAPK Regulation of Energy Metabolism in Skeletal Muscle Offers a Therapeutic Path for Type 2 Diabetes. | Bengal E et al. | β | 2025 | β |
| Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy. | Ma J et al. | β | 2025 | β |
| Perfluorooctane sulfonate exposure and alcohol-associated liver disease severity in a mouse chronic-binge ethanol feeding model. | Ekuban FA et al. | β | 2025 | β |
| Periodic dietary restriction of animal products induces metabolic reprogramming in humans with effects on cardiometabolic health. | Rouskas K et al. | β | 2025 | β |
| Potential application of mono-, dual-, and triple-target GLP-1 receptor agonists in improving the prognosis of patients with diabetic foot ulcers. | Li Z et al. | β | 2025 | β |
| Prominent fibroblast growth factor 21 with less abundant tumor-associated macrophages in hepatic mass of the conditional mgmt-deleted mice using LysM-Cre system. | Sontidejkul S et al. | β | 2025 | β |
| Protective Effects of Regular Physical Activity: Differential Expression of <i>FGF21</i>, <i>GDF15,</i> and Their Receptors in Trained and Untrained Individuals. | MaΕkowska P et al. | β | 2025 | β |
| Research progress on the role of FGF21 in insulin resistance. | Zhang H et al. | β | 2025 | β |
| Role of the serum levels of the inter-organs messenger fibroblast growth factor 21 (FGF21) in the diagnosis and prognosis of breast cancer patients. | Ranuncolo SM et al. | β | 2025 | β |
| Roles of myokines in osteoporosis under physiological and diabetic conditions. | Ji X et al. | β | 2025 | β |
| Saponins from <i>Panax japonicus</i> Enhance Lipolysis via Acting on FGF21-Ξ²-Klotho/FGFR1 in Obese Mice. | Wang T et al. | β | 2025 | β |
| Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside. | Huang Y et al. | β | 2025 | β |
| Sexual dimorphism of MASLD-driven bone loss. | Goldscheitter GM et al. | β | 2025 | β |
| Synergistic effect of canine FGF-21 combined with insulin in the treatment of canine diabetes. | Sun W et al. | β | 2025 | β |
| Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment. | Cui X et al. | β | 2025 | β |
| Temporal Transcriptomic Differences in Stroke Between Diabetic and Non-Diabetic Mice. | Lv Y et al. | β | 2025 | β |
| The Chimeric Peptide (GEP44) Reduces Body Weight and Both Energy Intake and Energy Expenditure in Diet-Induced Obese Rats. | Goldberg M et al. | β | 2025 | β |
| The circadian rhythm: A new target of natural products that can protect against diseases of the metabolic system, cardiovascular system, and nervous system. | Xin M et al. | β | 2025 | β |
| The effects of SGLT2 inhibitors on metabolic phenotype and FGF-21 expression from the adipose tissue and the liver are less pronounced in ob/ob mice. | Di Vincenzo A et al. | β | 2025 | β |
| The endocrine role of hepatokines: implications for human health and disease. | Iglesias P | β | 2025 | β |
| The Metabolic Transition Between Fasting and Feeding Alters Aging-Associated Metabolites, Lowers BCAAs, and Stimulates FGF21 Production in Humans. | Cagigas ML et al. | β | 2025 | β |
| The role of FGF21 in the metabolic adjustments required for exercise capacity. | Abe L et al. | β | 2025 | β |
| The role of the glucagon-FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition. | Moreno-Lopez M et al. | β | 2025 | β |
| Time-restricted feeding mitigates HFD-induced sarcopenic obesity in aging mice through improving the sensitivity of FGF21. | Wang T et al. | β | 2025 | β |
| Transcriptomic and metabolomic insights into the enantioselective effects of chiral fungicide penflufen and its enantiomers on multi-endpoints in the liver for mice. | Di S et al. | β | 2025 | β |
| Treating metabolic dysfunction-associated steatohepatitis: The fat-trimming FGF21 approach. | Li X et al. | β | 2025 | β |
| Unlocking the benefits of aerobic exercise for MAFLD: a comprehensive mechanistic analysis. | Zhang W et al. | β | 2025 | β |
| Whole-brain Mapping Reveals Diet-dependent Neuronal Activation and Selective Resistance to Exogenous FGF21. | Meng J et al. | β | 2025 | β |
| Acute effect of exercise intensity on circulating FGF-21, FSTL-1, cathepsin B, and BDNF in young men. | Ji M et al. | β | 2024 | β |
| Adipocyte Mitochondria: Deciphering Energetic Functions across Fat Depots in Obesity and Type 2 Diabetes. | Das S et al. | β | 2024 | β |
| Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV. | Ramirez Bustamante CE et al. | β | 2024 | β |
| Age of Cafeteria Diet Onset Influences Obesity Phenotype in Mice in a Sex-Specific Manner. | Bazhan N et al. | β | 2024 | β |
| A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system. | Aleman J et al. | β | 2024 | β |
| A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease. | Sahin C et al. | β | 2024 | β |
| Association of Low Vitamin D Status With Adiponectin and Fibroblast Growth Factor-21 in Newly Diagnosed Type 2 Diabetes Mellitus Patients. | Murugiah V et al. | β | 2024 | β |
| A Synergistic Botanical Composition Increases Resting Energy Expenditure and Reduces Adiposity in High-Fat Diet-Fed Rats. | Kundimi S et al. | β | 2024 | β |
| Beyond the Cold: Activating Brown Adipose Tissue as an Approach to Combat Obesity. | Negroiu CE et al. | β | 2024 | β |
| Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction. | GarcΓa-MartΓnez P et al. | β | 2024 | β |
| Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis. | Jia W et al. | β | 2024 | β |
| Biomarkers of mitochondrial disorders. | Shayota BJ | β | 2024 | β |
| BV2 Membrane-Coated PEGylated-Liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy. | Wang HC et al. | β | 2024 | β |
| Cold Exposure Rejuvenates the Metabolic Phenotype of <i>Panx1<sup>-/-</sup></i> Mice. | Molica F et al. | β | 2024 | β |
| Computer-aided engineering of stabilized fibroblast growth factor 21. | de La Bourdonnaye G et al. | β | 2024 | β |
| Critical role of FGF21 in diabetic kidney disease: from energy metabolism to innate immunity. | Liang Y et al. | β | 2024 | β |
| Crosstalk between pancreatic cancer and adipose tissue: Molecular mechanisms and therapeutic implications. | Diao B et al. | β | 2024 | β |
| Current status and future perspectives of FGF21 analogues in clinical trials. | Chui ZSW et al. | β | 2024 | β |
| Current views on etiology, diagnosis, epidemiology and gene therapy of maturity onset diabetes in the young. | Dzhemileva LU et al. | β | 2024 | β |
| Deciphering adipose development: Function, differentiation and regulation. | Guo G et al. | β | 2024 | β |
| Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog. | Sass-Γrum K et al. | β | 2024 | β |
| Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC). | Misceo D et al. | β | 2024 | β |
| Effect of a 6-Week Carbohydrate-Reduced High-Protein Diet on Levels of FGF21 and GDF15 in People With Type 2 Diabetes. | Richter MM et al. | β | 2024 | β |
| Effects of aquatic versus land-based exercise on irisin and fibroblast growth factor 21 expression and triiodothyronine and free fatty acid levels in elderly women. | Kang DW et al. | β | 2024 | β |
| Effects of central FGF21 infusion on the glucose homeostasis in rats (brain-pancreas axis). | Tanbek K et al. | β | 2024 | β |
| Effects of swimming in cold water on lipolysis indicators via fibroblast growth factor-21 in male Wistar rats. | Shams S et al. | β | 2024 | β |
| Endocrine FGFs and their signaling in the brain: Relevance for energy homeostasis. | Zangerolamo L et al. | β | 2024 | β |
| Endocrine fibroblast growth factors in domestic animals. | Brinker EJ et al. | β | 2024 | β |
| Endothelin receptor B-deficient mice are protected from high-fat diet-induced metabolic syndrome. | Feger M et al. | β | 2024 | β |
| Enhanced bioactivity and stability of a long-acting FGF21: A novel variant for the treatment of NASH. | Ji Y et al. | β | 2024 | β |
| Epigenetic Alterations in Alzheimer's Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems. | Greeny A et al. | β | 2024 | β |
| Evaluating Fibroblast Growth Factor 21 (FGF21) Levels Post-Gastric Sleeve Surgery in Obese Patients. | Al-Regaiey KA et al. | β | 2024 | β |
| Exploring endocrine FGFs - structures, functions and biomedical applications. | Phan P et al. | β | 2024 | β |
| FGF21 ameliorates diabetic nephropathy through CDK1-dependently regulating the cell cycle. | Zhang Y et al. | β | 2024 | β |
| FGF21 inhibits ferroptosis caused by mitochondrial damage to promote the repair of peripheral nerve injury. | Yan Y et al. | β | 2024 | β |
| FGF21 mediating the Sex-dependent Response to Dietary Macronutrients. | Soto Sauza KA et al. | β | 2024 | β |
| FGF21 protects against ischaemia reperfusion injury in normal and fatty livers. | Ma Y et al. | β | 2024 | β |
| Fibroblast growth factor 21. | Trusz GJ | β | 2024 | β |
| Fibroblast growth factor 21 alleviates acetaminophen induced acute liver injury by activating Sirt1 mediated autophagy. | Xu G et al. | β | 2024 | β |
| Fibroblast growth factor 21 alleviates unilateral ureteral obstruction-induced renal fibrosis by inhibiting Wnt/Ξ²-catenin signaling pathway. | Zhong W et al. | β | 2024 | β |
| Fibroblast Growth Factors in Cardiovascular Disease. | Morita H et al. | β | 2024 | β |
| Fructose-induced FGF21 secretion does not activate brown adipose tissue in Japanese young men: randomized cross-over and randomized controlled trials. | Kataoka H et al. | β | 2024 | β |
| Function and Regulation of Bone Marrow Adipose Tissue in Health and Disease: State of the Field and Clinical Considerations. | Zhang X et al. | β | 2024 | β |
| Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms. | Richter MM et al. | β | 2024 | β |
| Hepatic function of glucagon-like peptide-1 and its based diabetes drugs. | Feng JN et al. | β | 2024 | β |
| Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease. | Chui ZSW et al. | β | 2024 | β |
| Imbalanced Skeletal Muscle Mitochondrial Proteostasis Causes Bone Loss. | Jin Z et al. | β | 2024 | β |
| Improving Downstream Process Related Manufacturability Based on Protein Engineering-A Feasibility Study. | Capito F et al. | β | 2024 | β |
| Increased FGF-21 Improves Ectopic Lipid Deposition in the Liver and Skeletal Muscle. | Jia Y et al. | β | 2024 | β |
| Insights into the role of FGF21 in coronary heart disease. | Zhang QY et al. | β | 2024 | β |
| Intermittent Fasting-Induced Orm2 Promotes Adipose Browning via the GP130/IL23R-p38 Cascade. | Zhu X et al. | β | 2024 | β |
| Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease. | Fan YH et al. | β | 2024 | β |
| Ketone bodies promote epididymal white adipose expansion to alleviate liver steatosis in response to a ketogenic diet. | Zhao MF et al. | β | 2024 | β |
| Lipodystrophy in methylmalonic acidemia associated with elevated FGF21 and abnormal methylmalonylation. | Manoli I et al. | β | 2024 | β |
| Long-term effects of a fat-directed FGF21 gene therapy in aged female mice. | Anderson JM et al. | β | 2024 | β |
| Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto's Thyroiditis on Levothyroxine Substitution. | Berta E et al. | β | 2024 | β |
| Maternal overweight and obesity modify the association of serum fibroblast growth factor 21 levels with gestational diabetes mellitus: A nested case-control study. | Wu P et al. | β | 2024 | β |
| Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages. | Huai Q et al. | β | 2024 | β |
| Mitigation of gestational diabetes-induced endothelial dysfunction through FGF21-NRF2 pathway activation involving L-Cystine. | Sun C et al. | β | 2024 | β |
| Mitochondrial complex I inhibition triggers NAD<sup>+</sup>-independent glucose oxidation via successive NADPH formation, "futile" fatty acid cycling, and FADH<sub>2</sub> oxidation. | Abrosimov R et al. | β | 2024 | β |
| [Non-classical hormones from the fibroblast growth factor family]. | Gronskaia SA et al. | β | 2024 | β |
| Novel FGF21 analogues through structure-based optimization for therapeutic development. | Guo Y et al. | β | 2024 | β |
| Obesity, Osteoarthritis, and Myokines: Balancing Weight Management Strategies, Myokine Regulation, and Muscle Health. | Timofte DV et al. | β | 2024 | β |
| Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARΞ±. | Zhou W et al. | β | 2024 | β |
| Parkin depletion prevents the age-related alterations in the FGF21 system and the decline in white adipose tissue thermogenic function in mice. | Delgado-AnglΓ©s A et al. | β | 2024 | β |
| Pegbelfermin for reducing transaminase levels in patients with non-alcoholic steatohepatitis: a dose-response meta-analysis of randomized controlled trials. | Lu Y et al. | β | 2024 | β |
| Plasma FGF21 Concentration in Kidney Transplant Patients-Results from Prospective and Cross-Sectional Studies. | BartmaΕska M et al. | β | 2024 | β |
| Retinal and metabolic changes in a high-fat diet (HFD)+STZ model of Type II diabetes. | Phillips S et al. | β | 2024 | β |
| Role of liver FGF21-KLB signaling in ketogenic diet-induced amelioration of hepatic steatosis. | Guo W et al. | β | 2024 | β |
| Spatial transcriptomic landscape unveils immunoglobin-associated senescence as a hallmark of aging. | Ma S et al. | β | 2024 | β |
| Spermidine activates adipose tissue thermogenesis through autophagy and fibroblast growth factor 21. | Ni Y et al. | β | 2024 | β |
| Spop deficiency impairs adipogenesis and promotes thermogenic capacity in mice. | Li Q et al. | β | 2024 | β |
| Targeting FGFR for cancer therapy. | Zhang P et al. | β | 2024 | β |
| Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases. | Li X et al. | β | 2024 | β |
| Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy. | Habib S | β | 2024 | β |
| The association between fibroblast growth factor 21 with diabetes retinopathy among type 2 diabetes mellitus patients: a systematic review, meta-analysis, and meta-regression. | Basir H et al. | β | 2024 | β |
| The effects of 12 weeks of high-intensity interval training and moderate-intensity continuous training on FGF21, irisin, and myostatin in men with type 2 diabetes mellitus. | Riahy S | β | 2024 | β |
| The hepatokine FGF21 stopped lipogenesis and reduced testosterone production in mLTC-1 Leydig Cell Line. | Bourdon G et al. | β | 2024 | β |
| The role and mechanism of AMPK in pulmonary hypertension. | Hou J et al. | β | 2024 | β |
| The Role of Central and Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker of Anorexia Nervosa Reconceptualized as a Metabo-Psychiatric Disorder. | Cao J et al. | β | 2024 | β |
| The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review. | Negroiu CE et al. | β | 2024 | β |
| The role of nonmyocardial cells in the development of diabetic cardiomyopathy and the protective effects of FGF21: a current understanding. | Zhang T et al. | β | 2024 | β |
| Tibetan tea consumption prevents obesity by modulating the cellular composition and metabolic reprogramming of white adipose tissue. | Duan S et al. | β | 2024 | β |
| Transplantation of committed pre-adipocytes from brown adipose tissue improves whole-body glucose homeostasis. | Dewal RS et al. | β | 2024 | β |
| Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice. | Di Vincenzo A et al. | β | 2024 | β |
| Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8<sup>+</sup>TΒ cells. | Hu C et al. | β | 2024 | β |
| Weighing in on the role of brown adipose tissue for treatment of obesity. | Prapaharan B et al. | β | 2024 | β |
| A comparative study of metformin and nicotinamide riboside in alleviating tissue aging in rats. | Geng L et al. | β | 2023 | β |
| Adipokines as Clinically Relevant Therapeutic Targets in Obesity. | WΓΌrfel M et al. | β | 2023 | β |
| Adipokines in atherosclerosis: unraveling complex roles. | Luo J et al. | β | 2023 | β |
| Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease. | Chikamatsu M et al. | β | 2023 | β |
| An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. | Lee E et al. | β | 2023 | β |
| ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance. | Gomes D et al. | β | 2023 | β |
| Association of NAFLD with FGF21 Polygenic Hazard Score, and Its Interaction with Protein Intake Level in Korean Adults. | Lee HJ et al. | β | 2023 | β |
| Association of plasminogen activator inhibitor-1 and fibroblastic growth factor 21 in 3 groups of type 2 diabetes: Without overweight/obesity, free of insulin resistance, and without hepatosteatosis. | Takebe N et al. | β | 2023 | β |
| Berberine protects mice against type 2 diabetes by promoting PPARΞ³-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis. | Chen Y et al. | β | 2023 | β |
| Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. | Aaldijk AS et al. | β | 2023 | β |
| Blood biomarkers of mitochondrial disease-One for all or all for one? | Suomalainen A | β | 2023 | β |
| Cellular and Molecular Regulation of Exercise-A Neuronal Perspective. | Reddy I et al. | β | 2023 | β |
| Ceramide on the road to insulin resistance and immunometabolic disorders in transition dairy cows: driver or passenger? | Zhao Y et al. | β | 2023 | β |
| Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study. | Post A et al. | β | 2023 | β |
| Circulating leukocyte cell-derived chemotaxin 2 and fibroblast growth factor 21 are negatively associated with cardiorespiratory fitness in healthy volunteers. | Malaikah S et al. | β | 2023 | β |
| CRISPRa-based activation of Fgf21 and Fndc5 ameliorates obesity by promoting adipocytes browning. | Zhu H et al. | β | 2023 | β |
| Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity. | LΕrincz H et al. | β | 2023 | β |
| Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role? | Vankrunkelsven W et al. | β | 2023 | β |
| Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse. | Song T et al. | β | 2023 | β |
| Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. | Brown EA et al. | β | 2023 | β |
| Effects of NKT Cells on Metabolic Disorders Caused by High-Fat Diet Using CD1d-Knockout Mice. | Ishikawa H et al. | β | 2023 | β |
| Evaluation of endpoints for the study and diagnosis of mitochondrial toxicity and disease: a narrative review. | Gharti P et al. | β | 2023 | β |
| Exercise-Induced Fibroblast Growth Factor-21: A Systematic Review and Meta-Analysis. | Kim H et al. | β | 2023 | β |
| Exercise-induced intertissue communication: adipose tissue and the heart. | Blackwell JA et al. | β | 2023 | β |
| Exploring the correlation between serum fibroblast growth factor-21 levels and Sarcopenia: a systematic review and meta-analysis. | Liu H et al. | β | 2023 | β |
| FGF13-Sensitive Alteration of Parkin Safeguards Mitochondrial Homeostasis in Endothelium of Diabetic Nephropathy. | Sun J et al. | β | 2023 | β |
| FGF19 increases mitochondrial biogenesis and fusion in chondrocytes via the AMPKΞ±-p38/MAPK pathway. | Kan S et al. | β | 2023 | β |
| FGF21 alleviates adipose stem cell senescence via CD90 glycosylation-dependent glucose influx in remodeling healthy white adipose tissue. | Zhou Z et al. | β | 2023 | β |
| FGF21 alleviates endothelial mitochondrial damage and prevents BBB from disruption after intracranial hemorrhage through a mechanism involving SIRT6. | Wang R et al. | β | 2023 | β |
| FGF21 Depletion Attenuates Colitis through Intestinal Epithelial IL-22-STAT3 Activation in Mice. | Liu L et al. | β | 2023 | β |
| Fibroblast Growth Factor 21: A Fascinating Perspective on the Regulation of Muscle Metabolism. | Li S et al. | β | 2023 | β |
| Fibroblast growth factor 21 and bone homeostasis. | Tang Y et al. | β | 2023 | β |
| Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. | Yan B et al. | β | 2023 | β |
| Fibroblast growth factor 21 as a potential master regulator in metabolic disorders. | Velingkar A et al. | β | 2023 | β |
| Fibroblast growth factor 21 attenuates ventilator-induced lung injury by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway. | Ding P et al. | β | 2023 | β |
| Fibroblast Growth Factor 21 Has a Diverse Role in Energetic and Reproductive Physiological Functions of Female Beef Cattle. | Prezotto LD et al. | β | 2023 | β |
| Fibroblast Growth Factor 21 in Gestational Diabetes Mellitus and Type 2 Diabetes Mellitus. | Gawlik K et al. | β | 2023 | β |
| Fibroblast growth factor 21 in heart failure. | Tucker W et al. | β | 2023 | β |
| Fibroblast growth factor 21 in metabolic syndrome. | Yang M et al. | β | 2023 | β |
| Fibroblast growth factor 21 is an independent predictor of prevalent and incident obstructive sleep apnea. | Huang W et al. | β | 2023 | β |
| Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets. | Le TDV et al. | β | 2023 | β |
| Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis. | Yong G et al. | β | 2023 | β |
| Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges. | Tian H et al. | β | 2023 | β |
| Glibenclamide promotes FGF21 secretion in interscapular BAT and attenuates depression-like behaviors in male mice with HFD-induced obesity. | Kuo YY et al. | β | 2023 | β |
| Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy. | Hope DCD et al. | β | 2023 | β |
| Heating-mediated purification of active FGF21 and structure-based design of its variant with enhanced potency. | Jung YE et al. | β | 2023 | β |
| Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis. | Garruti G et al. | β | 2023 | β |
| Hepatokines: the missing link in the development of insulin resistance and hyperandrogenism in PCOS? | Stefanaki K et al. | β | 2023 | β |
| High circulating fibroblast growth factor-21 levels as a screening marker in fatty pancreas patients. | Han F et al. | β | 2023 | β |
| Hyper-expression of GFP-fused active hFGF21 in tobacco chloroplasts. | Wang Y et al. | β | 2023 | β |
| Hyperphagia of female UCP1-deficient mice blunts anti-obesity effects of FGF21. | Klein Hazebroek M et al. | β | 2023 | β |
| Influence of intermittent fasting on autophagy in the liver. | Ma YN et al. | β | 2023 | β |
| Intestinal Amino Acid Transport and Metabolic Health. | BrΓΆer S | β | 2023 | β |
| Investigation of the Proliferative Potential of FGF21 or FGF19 in Liver-Specific FGFR4-Deficient Mice. | WΓ€se K et al. | β | 2023 | β |
| Leucine supplementation in maternal high-fat diet alleviated adiposity and glucose intolerance of adult mice offspring fed a postweaning high-fat diet. | Kim J et al. | β | 2023 | β |
| LncRNA Nron deficiency protects mice from diet-induced adiposity and hepatic steatosis. | Liu B et al. | β | 2023 | β |
| Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes. | Brodosi L et al. | β | 2023 | β |
| Metabolism-Disrupting Chemicals Affecting the Liver: Screening, Testing, and Molecular Pathway Identification. | Fritsche K et al. | β | 2023 | β |
| Metformin Protects Rat Skeletal Muscle from Physical Exercise-Induced Injury. | Abbadessa G et al. | β | 2023 | β |
| Molecular mechanisms underlying physical exercise-induced brain BDNF overproduction. | Cefis M et al. | β | 2023 | β |
| New insights into the inter-organ crosstalk mediated by ChREBP. | Carbinatti T et al. | β | 2023 | β |
| Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease. | Oikonomou E et al. | β | 2023 | β |
| Pancreatic alpha cell glucagon-liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes. | Cui X et al. | β | 2023 | β |
| Partial skeletal muscle-specific Drp1 knockout enhances insulin sensitivity in diet-induced obese mice, but not in lean mice. | Kugler BA et al. | β | 2023 | β |
| Peelable Microneedle Patches Deliver Fibroblast Growth Factors to Repair Skin Photoaging Damage. | Yang G et al. | β | 2023 | β |
| Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy. | Amatya R et al. | β | 2023 | β |
| Physiological and molecular mechanisms of cold-induced improvements in glucose homeostasis in humans beyond brown adipose tissue. | van Beek S et al. | β | 2023 | β |
| Plasma proteomic signature of fatty liver disease: The Rotterdam Study. | Abozaid YJ et al. | β | 2023 | β |
| Reflections on the state of diabetes research and prospects for treatment. | Accili D et al. | β | 2023 | β |
| Role of Thyrotropin-Releasing Hormone in Regulating Fibroblast Growth Factor 21 in Mouse Pancreatic Ξ² Cells. | Garay Guerrero J et al. | β | 2023 | β |
| Serum Fibroblast Growth Factor-21 Discriminates Between Decompensated Alcohol-Associated Cirrhosis and Severe Alcohol-Associated Hepatitis. | McLean Diaz P et al. | β | 2023 | β |
| Serum Fibroblast Growth Factor 21 Level After an Oral Fat Tolerance Test is Related to Postprandial Free Fatty Acid Level. | Li X et al. | β | 2023 | β |
| Short-Term Decreasing and Increasing Dietary BCAA Have Similar, but Not Identical Effects on Lipid and Glucose Metabolism in Lean Mice. | Sun Y et al. | β | 2023 | β |
| [State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)]. | Grzych G et al. | β | 2023 | β |
| Structural basis for FGF hormone signalling. | Chen L et al. | β | 2023 | β |
| Substantial changes in inflammatory and cardiovascular biomarkers in patients with autonomous cortisol secretion. | Ueland GΓ et al. | β | 2023 | β |
| Sustained remission of type 2 diabetes in rodents by centrally administered fibroblast growth factor 4. | Sun H et al. | β | 2023 | β |
| Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action. | Chan J et al. | β | 2023 | β |
| Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. | Tan H et al. | β | 2023 | β |
| Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis. | Li G et al. | β | 2023 | β |
| The association of FGF-21 with the risk of newly diagnosed type-2 diabetes mellitus: a cross-sectional study in Southern China. | You L et al. | β | 2023 | β |
| The CEBPA-FGF21 regulatory network may participate in the T2DM-induced skeletal muscle atrophy by regulating the autophagy-lysosomal pathway. | Wu K et al. | β | 2023 | β |
| The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus. | JagodziΕska A et al. | β | 2023 | β |
| The effect of fibroblast growth factor 21 on a mouse model of bovine viral diarrhea. | Zhao D et al. | β | 2023 | β |
| The Effects of Rumen-Protected Choline and Rumen-Protected Nicotinamide on Liver Transcriptomics in Periparturient Dairy Cows. | Du X et al. | β | 2023 | β |
| The fibroblast growth factor system in cognitive disorders and dementia. | Zhai W et al. | β | 2023 | β |
| The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. | Finney AC et al. | β | 2023 | β |
| The Interplay of Adipokines and Pancreatic Beta Cells in Metabolic Regulation and Diabetes. | Kim J et al. | β | 2023 | β |
| The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers. | Rosenstock M et al. | β | 2023 | β |
| The pan-liver network theory: From traditional chinese medicine to western medicine. | Zhang Y et al. | β | 2023 | β |
| The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases. | Zanini G et al. | β | 2023 | β |
| The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise. | Lim JY et al. | β | 2023 | β |
| The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review. | Sadowska A et al. | β | 2023 | β |
| TNIK is a conserved regulator of glucose and lipid metabolism in obesity. | Pham TCP et al. | β | 2023 | β |
| Toward reconciling the roles of FGF21 in protein appetite, sweet preference, and energy expenditure. | Solon-Biet SM et al. | β | 2023 | β |
| Toxicokinetics of recombinant human fibroblast growth factor 21 for injection in cynomolgus monkey for 3Β months. | Lu C et al. | β | 2023 | β |
| Valproate-Induced Metabolic Syndrome. | Shnayder NA et al. | β | 2023 | β |
| Activating Connexin43 gap junctions primes adipose tissue for therapeutic intervention. | Zhu Y et al. | β | 2022 | β |
| Acute Deletion of the FOXO1-dependent Hepatokine FGF21 Does not Alter Basal Glucose Homeostasis or Lipolysis in Mice. | Sostre-ColΓ³n J et al. | β | 2022 | β |
| Acute retinol mobilization by retinol-binding protein 4 in mouse liver induces fibroblast growth factor 21 expression. | Steinhoff JS et al. | β | 2022 | β |
| Acute sleep loss alters circulating fibroblast growth factor 21 levels in humans: A randomised crossover trial. | Mateus BrandΓ£o LE et al. | β | 2022 | β |
| Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation. | Ren Y et al. | β | 2022 | β |
| AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21-mediated time-dependent mechanisms. | Wang Y et al. | β | 2022 | β |
| Alcoholic fatty liver is blunted by rFGF21 administration in mice lacking adipose FGFR1: The role of FGF21 in PPARΞ±-mediated regulation of adipose tissue mass. | Xu Y et al. | β | 2022 | β |
| An fgf21-like gene from swamp eel (Monopterus albus): Recombinant expression and its potential roles in glucose and lipid homeostasis. | Zheng S et al. | β | 2022 | β |
| Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver. | Yang R et al. | β | 2022 | β |
| Anti-obesity drug discovery: advances and challenges. | MΓΌller TD et al. | β | 2022 | β |
| Association between amorphous calcium-phosphate ratios in circulating calciprotein particles and prognostic biomarkers in hemodialysis patients. | Nakamura K et al. | β | 2022 | β |
| Association of serum fibroblast growth factor 21 levels with skeletal muscle mass and mortality in chronic hemodialysis patients. | Chiu LT et al. | β | 2022 | β |
| Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus. | Taniguchi H et al. | β | 2022 | β |
| Autocrine FGF1 signaling promotes glucose uptake in adipocytes. | Nies VJM et al. | β | 2022 | β |
| Beneficial Effects of Table Grape Use on Serum Levels of Omega-3 Index and Liver Function: A Randomized Controlled Clinical Trial. | Notarnicola M et al. | β | 2022 | β |
| Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. | Christoffersen BΓ et al. | β | 2022 | β |
| Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021. | She QY et al. | β | 2022 | β |
| Biomarkers in metabolic syndrome. | Cho YH et al. | β | 2022 | β |
| Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome. | Khasanova AK et al. | β | 2022 | β |
| Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases. | Machado SA et al. | β | 2022 | β |
| Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. | van Deuren T et al. | β | 2022 | β |
| Change of Fibroblast Growth Factor 21 Level Correlates with the Severity of Diabetic Sensory Polyneuropathy after Six-Week Physical Activity. | MolnΓ‘r Γ et al. | β | 2022 | β |
| Circadian clock controls rhythms in ketogenesis by interfering with PPARΞ± transcriptional network. | Mezhnina V et al. | β | 2022 | β |
| Circadian stabilization loop: the regulatory hub and therapeutic target promoting circadian resilience and physiological health. | Kim E et al. | β | 2022 | β |
| Circulating FGF21 vs. Stress Markers in Girls during Childhood and Adolescence, and in Their Caregivers: Intriguing Inter-Relations between Overweight/Obesity, Emotions, Behavior, and the Cared-Caregiver Relationship. | Christaki EV et al. | β | 2022 | β |
| Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor Ξ± Modulator (SPPARMΞ±), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARΞ± in Mice. | Zhang Z et al. | β | 2022 | β |
| Combined genetic deletion of GDF15 and FGF21 has modest effects on body weight, hepatic steatosis and insulin resistance in high fat fed mice. | Patel S et al. | β | 2022 | β |
| Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. | Puengel T et al. | β | 2022 | β |
| Contribution of Liver and Pancreatic Islet Crosstalk to Ξ²-Cell Function/Dysfunction in the Presence of Fatty Liver. | LΓ³pez-Bermudo L et al. | β | 2022 | β |
| Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. | Vachher M et al. | β | 2022 | β |
| Defining the Roles of Cardiokines in Human Aging and Age-Associated Diseases. | Srivastava H et al. | β | 2022 | β |
| Delayed rFGF21 Administration Improves Cerebrovascular Remodeling and White Matter Repair After Focal Stroke in Diabetic Mice. | Jiang Y et al. | β | 2022 | β |
| Do Sugar-Sweetened Beverages Increase Fasting FGF21 Irrespective of the Type of Added Sugar? A Secondary Exploratory Analysis of a Randomized Controlled Trial. | Geidl-Flueck B et al. | β | 2022 | β |
| E4orf1 Prevents Progression of Fatty Liver Disease in Mice on High Fat Diet. | Afruza R et al. | β | 2022 | β |
| Effects of Fibroblast Growth Factor 21 on Lactate Uptake and Usage in Mice with Diabetes-Associated Cognitive Decline. | Zhao L et al. | β | 2022 | β |
| Effects of Mitochondrial Dynamics in the Pathophysiology of Obesity. | Wang J et al. | β | 2022 | β |
| Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. | Liao CJ et al. | β | 2022 | β |
| Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. | Tillman EJ et al. | β | 2022 | β |
| Emerging roles of fibroblast growth factor 21 in critical disease. | Yan F et al. | β | 2022 | β |
| Endocrine Fibroblast Growth Factors in Relation to Stress Signaling. | Shimizu M et al. | β | 2022 | β |
| FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. | SzczepaΕska E et al. | β | 2022 | β |
| FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes. | Samms RJ et al. | β | 2022 | β |
| FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk. | Chaffin AT et al. | β | 2022 | β |
| FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism. | SzczepaΕska E et al. | β | 2022 | β |
| FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity. | Jin L et al. | β | 2022 | β |
| FGF4, A New Potential Regulator in Gestational Diabetes Mellitus. | Fan M et al. | β | 2022 | β |
| FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis. | Song L et al. | β | 2022 | β |
| Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next. | Jin T | β | 2022 | β |
| Fibroblast Growth Factor 21 Facilitates the Homeostatic Control of Feeding Behavior. | Wu CT et al. | β | 2022 | β |
| Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients. | Corbee RJ et al. | β | 2022 | β |
| Fibroblast growth factor 21 (FGF21) promotes porcine granulosa cell estradiol production and proliferation via PI3K/AKT/mTOR signaling. | Hu Y et al. | β | 2022 | β |
| Fibroblast growth factor-21 improves insulin action in nonlactating ewes. | Lamb CL et al. | β | 2022 | β |
| Fibroblast growth factor 21 is associated with widening QRS complex and prolonged corrected QT interval in patients with stable angina. | Hung WC et al. | β | 2022 | β |
| Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Metabolically Healthy and Metabolically Unhealthy Obese Children | Akduman F et al. | β | 2022 | β |
| Fibroblast growth factor 21 reverses high-fat diet-induced impairment of vascular function via the anti-oxidative pathway in ApoE knockout mice. | Huang WP et al. | β | 2022 | β |
| Fibroblast Growth Factors and Cellular Communication Network Factors: Intimate Interplay by the Founding Members in Cartilage. | Kubota S et al. | β | 2022 | β |
| Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression. | Lee KM et al. | β | 2022 | β |
| Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH. | Larsson SC et al. | β | 2022 | β |
| Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. | Yadav P et al. | β | 2022 | β |
| Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery. | Karason K et al. | β | 2022 | β |
| Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance. | Qiao L et al. | β | 2022 | β |
| Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers. | Sui Y et al. | β | 2022 | β |
| Hepatic hormone FGF21 and its analogues in clinical trials. | Shao W et al. | β | 2022 | β |
| Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk. | Berthou F et al. | β | 2022 | β |
| Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice. | Yano K et al. | β | 2022 | β |
| Hepatokine ERAP1 Disturbs Skeletal Muscle Insulin Sensitivity Via Inhibiting USP33-Mediated ADRB2 Deubiquitination. | Niu Y et al. | β | 2022 | β |
| Impact of moderate dietary protein restriction on glucose homeostasis in a model of estrogen deficiency. | Fournier C et al. | β | 2022 | β |
| Intermittent methionine restriction reduces IGF-1 levels and produces similar healthspan benefits to continuous methionine restriction. | Plummer JD et al. | β | 2022 | β |
| Ketone body and FGF21 coordinately regulate fasting-induced oxidative stress response in the heart. | Kawakami R et al. | β | 2022 | β |
| Liver Brain Interactions: Focus on FGF21 a Systematic Review. | Prida E et al. | β | 2022 | β |
| LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. | Rader DJ et al. | β | 2022 | β |
| Long-Term Dietary Taurine Lowers Plasma Levels of Cholesterol and Bile Acids. | Tagawa R et al. | β | 2022 | β |
| Maternal Blood-Based Protein Biomarkers in Relation to Abdominal Fat Distribution Measured by Ultrasound in Early Mid-Pregnancy. | Lindberger E et al. | β | 2022 | β |
| Maternal Fibroblast Growth Factor 21 Levels Decrease during Early Pregnancy in Normotensive Pregnant Women but Are Higher in Preeclamptic Women-A Longitudinal Study. | Buell-Acosta JD et al. | β | 2022 | β |
| Mitochondrial proteostasis stress in muscle drives a long-range protective response to alleviate dietary obesity independently of ATF4. | Guo Q et al. | β | 2022 | β |
| Molecular mechanisms of dietary restriction promoting health and longevity. | Green CL et al. | β | 2022 | β |
| More than meets the islet: aligning nutrient and paracrine inputs with hormone secretion in health and disease. | Morriseau TS et al. | β | 2022 | β |
| Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression. | Huang Q et al. | β | 2022 | β |
| New developments in the biology of fibroblast growth factors. | Ornitz DM et al. | β | 2022 | β |
| Novel Adipokines CTRP1, CTRP9, and FGF21 in Pediatric Type 1 and Type 2 Diabetes: A Cross-Sectional Analysis. | Arking A et al. | β | 2022 | β |
| Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis. | Scheja L et al. | β | 2022 | β |
| Nuclear Receptors in Energy Metabolism. | Walth-Hummel AA et al. | β | 2022 | β |
| Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. | Puengel T et al. | β | 2022 | β |
| Performance and Metabolic, Inflammatory, and Oxidative Stress-Related Parameters in Early Lactating Dairy Cows with High and Low Hepatic FGF21 Expression. | Gessner DK et al. | β | 2022 | β |
| Pharmacological FGF21 signals to glutamatergic neurons to enhance leptin action and lower body weight during obesity. | Claflin KE et al. | β | 2022 | β |
| Plasma FGF-21 and Sclerostin Levels, Glycemia, Adiposity, and Insulin Sensitivity in Normoglycemic Black and White Adults. | Umekwe N et al. | β | 2022 | β |
| Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans. | Solomon TPJ et al. | β | 2022 | β |
| Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication. | Furuhashi M et al. | β | 2022 | β |
| Preliminary Study of Serum Biomarkers Associated With Delirium After Major Cardiac Surgery. | McKay TB et al. | β | 2022 | β |
| Prenatal dexamethasone exposure induced pancreatic Ξ²-cell dysfunction and glucose intolerance of male offspring rats: Role of the epigenetic repression of ACE2. | Dai Y et al. | β | 2022 | β |
| Reactive Oxygen and Nitrogen Species (RONS) and Cytokines-Myokines Involved in Glucose Uptake and Insulin Resistance in Skeletal Muscle. | Llanos P et al. | β | 2022 | β |
| Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression. | Kim HY et al. | β | 2022 | β |
| Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases. | Jia MQ et al. | β | 2022 | β |
| Role of circulating molecules in age-related cardiovascular and metabolic disorders. | Hsiao YT et al. | β | 2022 | β |
| Seed- and leaf-based expression of FGF21-transferrin fusion proteins for oral delivery and treatment of non-alcoholic steatohepatitis. | Hou HW et al. | β | 2022 | β |
| Serum Fibroblast Growth Factor 21 Level Is Associated with Aortic Stiffness in Patients on Maintenance Hemodialysis. | Chiu LT et al. | β | 2022 | β |
| Sexual Dimorphism in Adipose-Hypothalamic Crosstalk and the Contribution of Aryl Hydrocarbon Receptor to Regulate Energy Homeostasis. | Haque N et al. | β | 2022 | β |
| Short Term Isocaloric Ketogenic Diet Modulates NLRP3 Inflammasome <i>Via</i> B-hydroxybutyrate and Fibroblast Growth Factor 21. | Kim ER et al. | β | 2022 | β |
| Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalities. | Pedersen AKN et al. | β | 2022 | β |
| Spontaneous Browning of White Adipose Tissue Improves Angiogenesis and Reduces Macrophage Infiltration After Fat Grafting in Mice. | Lin J et al. | β | 2022 | β |
| Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice. | Bartesaghi S et al. | β | 2022 | β |
| Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway. | Wu YK et al. | β | 2022 | β |
| Suppression of obesity by melatonin through increasing energy expenditure and accelerating lipolysis in mice fed a high-fat diet. | Xu L et al. | β | 2022 | β |
| Symposium review: Adipose tissue endocrinology in the periparturient period of dairy cows. | HΓ€ussler S et al. | β | 2022 | β |
| The effect of different weight loss strategies to treat non-alcoholic fatty liver disease focusing on fibroblast growth factor 21. | Power Guerra N et al. | β | 2022 | β |
| The New Markers of Early Obesity-Related Organ and Metabolic Abnormalities. | Ziomber-Lisiak A et al. | β | 2022 | β |
| The Origins, Evolution, and Future of Dietary Methionine Restriction. | Fang H et al. | β | 2022 | β |
| The potential function and clinical application of FGF21 in metabolic diseases. | Chen Z et al. | β | 2022 | β |
| The potential therapeutic effect of klotho on cell viability in human colorectal adenocarcinoma HT-29 cells. | Sariboyaci AE et al. | β | 2022 | β |
| The Role of Crosstalk between Adipose Cells and Myocytes in the Pathogenesis of Sarcopenic Obesity in the Elderly. | Zamboni M et al. | β | 2022 | β |
| The Slc25a47 locus is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis. | Bresciani N et al. | β | 2022 | β |
| Type 2 Diabetes Mellitus: Pathogenic Features and Experimental Models in Rodents. | Gvazava IG et al. | β | 2022 | β |
| Uncoupling Protein-1 Modulates Anxiety-Like Behavior in a Temperature-Dependent Manner. | Sideromenos S et al. | β | 2022 | β |
| Wogonin, a Compound in <i>Scutellaria baicalensis</i>, Activates ATF4-FGF21 Signaling in Mouse Hepatocyte AML12 Cells. | Yamada Y et al. | β | 2022 | β |
| Advances in Biological Functions and Clinical Studies of FGF21. | Lin W et al. | β | 2021 | β |
| Ahnak deficiency attenuates high-fat diet-induced fatty liver in mice through FGF21 induction. | Kim YN et al. | β | 2021 | β |
| Altered adipokines in obese adolescents: a cross-sectional and longitudinal analysis across the spectrum of glycemia. | Wolf RM et al. | β | 2021 | β |
| A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. | Pan Q et al. | β | 2021 | β |
| Association between serum FGF21 level and sarcopenia in older adults. | Jung HW et al. | β | 2021 | β |
| Association of Elevated Plasma FGF21 and Activated FGF21 Signaling in Visceral White Adipose Tissue and Improved Insulin Sensitivity in Gestational Diabetes Mellitus Subtype: A Case-Control Study. | Wang N et al. | β | 2021 | β |
| Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort. | Zhang R et al. | β | 2021 | β |
| Attenuation of FGF21 signalling might aggravate the impairment of glucose homeostasis during the high sucrose diet induced transition from prediabetes to diabetes in WNIN/GR-Ob rats. | Kondeti S et al. | β | 2021 | β |
| Beneficial effects of whole-body cryotherapy on glucose homeostasis and amino acid profile are associated with a reduced myostatin serum concentration. | KozΕowska M et al. | β | 2021 | β |
| Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies. | Hua S et al. | β | 2021 | β |
| Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. | Cheng L et al. | β | 2021 | β |
| Brown/Beige adipose tissues and the emerging role of their secretory factors in improving metabolic health: The batokines. | Ahmad B et al. | β | 2021 | β |
| Changes and significance of serum FGF21 in children with primary nephrotic syndrome and chronic renal failure. | Wei N et al. | β | 2021 | β |
| Chronic exposure to PFO4DA and PFO5DoDA, two perfluoroalkyl ether carboxylic acids (PFECAs), suppresses hepatic stress signals and disturbs glucose and lipid metabolism in male mice. | Chen J et al. | β | 2021 | β |
| CREBH Systemically Regulates Lipid Metabolism by Modulating and Integrating Cellular Functions. | Nakagawa Y et al. | β | 2021 | β |
| Deficiency of Cathelicidin Attenuates High-Fat Diet Plus Alcohol-Induced Liver Injury through FGF21/Adiponectin Regulation. | Li F et al. | β | 2021 | β |
| Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus. | IanoΘ RD et al. | β | 2021 | β |
| Differential effects of protein intake versus intake of a defined oligopeptide on FGF-21 in obese human subjects inΒ vivo. | Fangmann D et al. | β | 2021 | β |
| Differential roles of GDF15 and FGF21 in systemic metabolic adaptation to the mitochondrial integrated stress response. | Kang SG et al. | β | 2021 | β |
| Direct Targets and Subsequent Pathways for Molecular Hydrogen to Exert Multiple Functions: Focusing on Interventions in Radical Reactions. | Ohta S | β | 2021 | β |
| Distinct roles of UVRAG and EGFR signaling in skeletal muscle homeostasis. | Kim MJ et al. | β | 2021 | β |
| Drinking Molecular Hydrogen Water Is Beneficial to Cardiovascular Function in Diet-Induced Obesity Mice. | Masuda H et al. | β | 2021 | β |
| Dynamic folding modulation generates FGF21 variant against diabetes. | Zhu L et al. | β | 2021 | β |
| Early arteriosclerosis and its risk factors in subjects with prediabetes and new-onset diabetes. | Liu X et al. | β | 2021 | β |
| Effect of high-intensity circuit training on obesity indices, physical fitness, and browning factors in inactive female college students. | Lee JS et al. | β | 2021 | β |
| Effects of Bariatric Surgeries on Fetuin-A, Selenoprotein P, Angiopoietin-Like Protein 6, and Fibroblast Growth Factor 21 Concentration. | Poloczek J et al. | β | 2021 | β |
| Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model. | Kim JH et al. | β | 2021 | β |
| Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. | Yokote K et al. | β | 2021 | β |
| FGF19 and FGF21: In NASH we trust. | Talukdar S et al. | β | 2021 | β |
| FGF21 and Chronic Kidney Disease. | Salgado JV et al. | β | 2021 | β |
| FGF21 attenuates hypoxiaβinduced dysfunction and inflammation in HPAECs via the microRNAβ27bβmediated PPARΞ³ pathway. | Yao D et al. | β | 2021 | β |
| FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway. | Dai H et al. | β | 2021 | β |
| FGF21 Induced by the ASK1-p38 Pathway Promotes Mechanical Cell Competition by Attracting Cells. | Ogawa M et al. | β | 2021 | β |
| FGF21 in obesity and cancer: New insights. | Lu W et al. | β | 2021 | β |
| FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction. | Diener JL et al. | β | 2021 | β |
| FGF21 promotes ischaemic angiogenesis and endothelial progenitor cells function under diabetic conditions in an AMPK/NAD+-dependent manner. | Dai Q et al. | β | 2021 | β |
| FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). | Urraza-Robledo AI et al. | β | 2021 | β |
| Fibroblast growth factor 21: a novel long-acting hypoglycemic drug for canine diabetes. | Jiang X et al. | β | 2021 | β |
| Fibroblast Growth Factor 21 as a Potential Biomarker for Improved Locomotion and Olfaction Detection Ability after Weight Reduction in Obese Mice. | Power Guerra N et al. | β | 2021 | β |
| Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis. | Wu A et al. | β | 2021 | β |
| Fibroblast Growth Factor 21 (FGF21) Administration Sex-Specifically Affects Blood Insulin Levels and Liver Steatosis in Obese <i>A<sup>y</sup></i> Mice. | Makarova E et al. | β | 2021 | β |
| Fibroblast growth factor 21 (FGF21) is a sensitive marker of osteoporosis in haemodialysis patients: a cross-sectional observational study. | Zhu L et al. | β | 2021 | β |
| Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance. | Eder K et al. | β | 2021 | β |
| Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease. | GΓ³mez-SΓ‘mano MΓ et al. | β | 2021 | β |
| Fibroblast Growth Factor 21 Predicts and Promotes Vascular Calcification in Haemodialysis Patients. | Jiang L et al. | β | 2021 | β |
| Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. | Liang C et al. | β | 2021 | β |
| FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice. | Lee YK et al. | β | 2021 | β |
| FoxO1 suppresses Fgf21 during hepatic insulin resistance to impair peripheral glucose utilization and acute cold tolerance. | StΓΆhr O et al. | β | 2021 | β |
| Glucagon receptor signaling regulates weight loss via central KLB receptor complexes. | Nason SR et al. | β | 2021 | β |
| Glucagon's Metabolic Action in Health and Disease. | Zeigerer A et al. | β | 2021 | β |
| Gut microbiota mediate the FGF21 adaptive stress response to chronic dietary protein-restriction in mice. | Martin A et al. | β | 2021 | β |
| Hepatic AKT orchestrates adipose tissue thermogenesis via FGF21-dependent and -independent mechanisms. | Sostre-ColΓ³n J et al. | β | 2021 | β |
| Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. | Liu D et al. | β | 2021 | β |
| Hepatokines and metabolism: Deciphering communication from the liver. | Jensen-Cody SO et al. | β | 2021 | β |
| HIV-1 Viral Protein R Couples Metabolic Inflexibility With White Adipose Tissue Thermogenesis. | Agarwal N et al. | β | 2021 | β |
| Increased Fibroblast Growth Factor 21 (FGF21) Concentration in Early Second Trimester Amniotic Fluid and Its Association with Fetal Growth. | Vrachnis N et al. | β | 2021 | β |
| Increased plasma apoM levels impair triglyceride turnover in mice. | Hajny S et al. | β | 2021 | β |
| Inducible hepatic expression of CREBH mitigates diet-induced obesity, insulin resistance, and hepatic steatosis in mice. | Krumm CS et al. | β | 2021 | β |
| Leptin, Acting at Central Level, Increases FGF21 Expression in White Adipose Tissue via PPARΞ²/Ξ΄. | Mazuecos L et al. | β | 2021 | β |
| Levels of Ξ²-klotho determine the thermogenic responsiveness of adipose tissues: involvement of the autocrine action of FGF21. | Moure R et al. | β | 2021 | β |
| Metabolic Changes of Hepatocytes in NAFLD. | Lu Q et al. | β | 2021 | β |
| Metabolic Disturbances in Rat Sublines with Constitutionally Altered Serotonin Homeostasis. | KesiΔ M et al. | β | 2021 | β |
| Metabolic Messengers: FGF21. | Flippo KH et al. | β | 2021 | β |
| MiR-21-3p Inhibits Adipose Browning by Targeting FGFR1 and Aggravates Atrial Fibrosis in Diabetes. | Pan JA et al. | β | 2021 | β |
| Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. | Ajaz S et al. | β | 2021 | β |
| Mitochondrial Unfolded Protein Responses in White Adipose Tissue: Lipoatrophy, Whole-Body Metabolism and Lifespan. | Kobayashi M et al. | β | 2021 | β |
| Neuroprotective Effects of the FGF21 Analogue LY2405319. | RΓΌhlmann C et al. | β | 2021 | β |
| Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? | Di Ciaula A et al. | β | 2021 | β |
| Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine. | Fang H et al. | β | 2021 | β |
| Obesity and Pancreatic Cancer: Insight into Mechanisms. | Eibl G et al. | β | 2021 | β |
| Optogenetic delivery of trophic signals in a genetic model of Parkinson's disease. | Ingles-Prieto A et al. | β | 2021 | β |
| Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity. | Luo Y et al. | β | 2021 | β |
| Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects. | Ying L et al. | β | 2021 | β |
| Pathophysiological Implications of Imbalances in Fibroblast Growth Factor 23 in the Development of Diabetes. | Donate-Correa J et al. | β | 2021 | β |
| Pathophysiology of NASH in endocrine diseases. | Gariani K et al. | β | 2021 | β |
| Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys. | Thompson KE et al. | β | 2021 | β |
| Postprandial dynamics and response of fibroblast growth factor 21 in older adults. | Herpich C et al. | β | 2021 | β |
| PPARΞ± agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1. | Xu Y et al. | β | 2021 | β |
| Prognostic value of plasma fibroblast growth factor 21 among patients with acute ischemic stroke. | Zheng X et al. | β | 2021 | β |
| Protein metabolism and related body function: mechanistic approaches and health consequences. | TomΓ© D et al. | β | 2021 | β |
| Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). | Grattagliano I et al. | β | 2021 | β |
| Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease. | Zhou X et al. | β | 2021 | β |
| Regulation of diurnal energy balance by mitokines. | Klaus S et al. | β | 2021 | β |
| Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus. | Guo C et al. | β | 2021 | β |
| Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Energy Homeostasis of Dairy Animals: Exploiting Their Modulation through Nutrigenomic Interventions. | Hassan FU et al. | β | 2021 | β |
| Selenium supplementation inhibits IGF-1 signaling and confers methionine restriction-like healthspan benefits to mice. | Plummer JD et al. | β | 2021 | β |
| Serum FGF21 levels are altered by various factors including lifestyle behaviors in male subjects. | Nakanishi K et al. | β | 2021 | β |
| Severe protein deficiency induces hepatic expression and systemic level of FGF21 but inhibits its hypothalamic expression in growing rats. | Moro J et al. | β | 2021 | β |
| Short and long-term effects of high-intensity interval training applied alone or with whole-body cryostimulation on glucose homeostasis and myokine levels in overweight to obese subjects. | KozΕowska-Flis M et al. | β | 2021 | β |
| Skeletal endocrinology: where evolutionary advantage meets disease. | Jaschke N et al. | β | 2021 | β |
| Skeletal Muscle and Bone - Emerging Targets of Fibroblast Growth Factor-21. | Sun H et al. | β | 2021 | β |
| Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice. | Liu XH et al. | β | 2021 | β |
| Starvation-induced transcription factor CREBH negatively governs body growth by controlling GH signaling. | Nakagawa Y et al. | β | 2021 | β |
| Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling. | Agrawal S et al. | β | 2021 | β |
| Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. | Finotti M et al. | β | 2021 | β |
| Temperature-responsive structural reversibility of FGF21 and structure-based design of its variant with enhanced potency | Jung Y et al. | β | 2021 | β |
| Temporal metabolic and transcriptomic characteristics crossing islets and liver reveal dynamic pathophysiology in diet-induced diabetes. | Gao R et al. | β | 2021 | β |
| Th2 Cytokines Increase the Expression of Fibroblast Growth Factor 21 in the Liver. | Kang SG et al. | β | 2021 | β |
| The acute transcriptional responses to dietary methionine restriction are triggered by inhibition of ternary complex formation and linked to Erk1/2, mTOR, and ATF4. | Stone KP et al. | β | 2021 | β |
| The dynamics of human bone marrow adipose tissue in response to feeding and fasting. | Fazeli PK et al. | β | 2021 | β |
| The Effect of FGF21 and Its Genetic Variants on Food and Drug Cravings, Adipokines and Metabolic Traits. | Epperlein S et al. | β | 2021 | β |
| The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine. | Burow P et al. | β | 2021 | β |
| The Multifunctional Contribution of FGF Signaling to Cardiac Development, Homeostasis, Disease and Repair. | Khosravi F et al. | β | 2021 | β |
| The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model. | Spann RA et al. | β | 2021 | β |
| The PPARΞ± and PPARΞ³ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders. | Porcuna J et al. | β | 2021 | β |
| The protective effect of sulforaphane on type II diabetes induced by high-fat diet and low-dosage streptozotocin. | Tian S et al. | β | 2021 | β |
| Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. | Shah N et al. | β | 2021 | β |
| Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. | Kumar V et al. | β | 2021 | β |
| The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms. | Xiao M et al. | β | 2021 | β |
| The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology. | Li B et al. | β | 2021 | β |
| The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases. | Yan J et al. | β | 2021 | β |
| The Saga of Endocrine FGFs. | Phan P et al. | β | 2021 | β |
| The Same Metabolic Response to FGF21 Administration in Male and Female Obese Mice Is Accompanied by Sex-Specific Changes in Adipose Tissue Gene Expression. | Makarova E et al. | β | 2021 | β |
| The Transcriptome and Epigenome Reveal Novel Changes in Transcription Regulation During Pancreatic Rat Islet Maturation. | Lien YC et al. | β | 2021 | β |
| Ultrasound-assisted C<sub>3</sub>F<sub>8</sub>-filled PLGA nanobubbles for enhanced FGF21 delivery and improved prophylactic treatment of diabetic cardiomyopathy. | Gao J et al. | β | 2021 | β |
| Uninephrectomy and class II PI3K-C2Ξ² inactivation synergistically protect against obesity, insulin resistance and liver steatosis in mice. | Alliouachene S et al. | β | 2021 | β |
| Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice. | Queen NJ et al. | β | 2021 | β |
| What does self-selection of dietary proteins in rats tell us about protein requirements and body weight control? | Even PC et al. | β | 2021 | β |
| Ξ²2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. | Rao S et al. | β | 2021 | β |
| Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: A meta-analysis. | Lin Y et al. | β | 2020 | β |
| Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. | Chait A et al. | β | 2020 | β |
| Alcohol ingestion induces pancreatic islet dysfunction and apoptosis via mediation of FGF21 resistance. | Yang BC et al. | β | 2020 | β |
| Altered Transcription Factor Binding and Gene Bivalency in Islets of Intrauterine Growth Retarded Rats. | Lien YC et al. | β | 2020 | β |
| Association of circulating FGF-21 levels in the first week of life and postnatal growth in hospitalized preterm infants. | Joung KE et al. | β | 2020 | β |
| Basic Mechanisms of Diabetic Heart Disease. | Ritchie RH et al. | β | 2020 | β |
| Caloric Restriction Reprograms the Single-Cell Transcriptional Landscape of Rattus Norvegicus Aging. | Ma S et al. | β | 2020 | β |
| Calorie restriction for enhanced longevity: The role of novel dietary strategies in the present obesogenic environment. | Dorling JL et al. | β | 2020 | β |
| Circulating Diabetic Candidate Neurotrophic Factors, Brain-Derived Neurotrophic Factor and Fibroblast Growth Factor 21, in Sleeve Gastrectomy. | Yen HH et al. | β | 2020 | β |
| Circulating FGF21 Levels in Human Health and Metabolic Disease. | Keuper M et al. | β | 2020 | β |
| Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | Polyzos SA et al. | β | 2020 | β |
| Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects. | Watanabe H et al. | β | 2020 | β |
| Dietary Methionine Restriction Signals to the Brain Through Fibroblast Growth Factor 21 to Regulate Energy Balance and Remodeling of Adipose Tissue. | Forney LA et al. | β | 2020 | β |
| Digenic Variants in the FGF21 Signaling Pathway Associated with Severe Insulin Resistance and Pseudoacromegaly. | Stone SI et al. | β | 2020 | β |
| Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects. | Cho JM et al. | β | 2020 | β |
| Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women. | Ramanjaneya M et al. | β | 2020 | β |
| Dysregulated Autophagy Mediates Sarcopenic Obesity and Its Complications via AMPK and PGC1Ξ± Signaling Pathways: Potential Involvement of Gut Dysbiosis as a Pathological Link. | Ryu JY et al. | β | 2020 | β |
| Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model. | Maeng HJ et al. | β | 2020 | β |
| Effects of beta-conglycinin intake on circulating FGF21 levels and brown adipose tissue activity in Japanese young men: a single intake study and a randomized controlled trial. | Taniguchi H et al. | β | 2020 | β |
| Endocrinological Features of Hartsfield Syndrome in an Adult Patient With a Novel Mutation of <i>FGFR1</i>. | Kobayashi S et al. | β | 2020 | β |
| Exercise-Released Myokines in the Control of Energy Metabolism. | Laurens C et al. | β | 2020 | β |
| FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. | Henriksson E et al. | β | 2020 | β |
| FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment. | Ruiz-Padilla AJ et al. | β | 2020 | β |
| FGF21 and the Physiological Regulation of Macronutrient Preference. | Hill CM et al. | β | 2020 | β |
| FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. | Tillman EJ et al. | β | 2020 | β |
| FGF21 Mimics a Fasting-Induced Metabolic State and Increases Appetite in Zebrafish. | Blanco AM et al. | β | 2020 | β |
| FGF/FGFR signaling in health and disease. | Xie Y et al. | β | 2020 | β |
| Fibroblast growth factor 1 ameliorates adipose tissue inflammation and systemic insulin resistance via enhancing adipocyte mTORC2/Rictor signal. | Zhao L et al. | β | 2020 | β |
| Fibroblast growth factor 21 and autophagy: A complex interplay in Parkinson disease. | Kakoty V et al. | β | 2020 | β |
| Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6. | Eckard AR et al. | β | 2020 | β |
| Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. | Wu L et al. | β | 2020 | β |
| Fibroblast Growth Factor-21, Leptin, and Adiponectin Responses to Acute Cold-Induced Brown Adipose Tissue Activation. | Sun L et al. | β | 2020 | β |
| Impact of adipokines and myokines on fat browning. | RodrΓguez A et al. | β | 2020 | β |
| Is ursodeoxycholic acid therapy due to pregnant intrahepatic cholestasis change the adiponectin and fibroblast growth factor-21 levels?-Pilot study. | Kierach R et al. | β | 2020 | β |
| Klotho and fibroblast growth factors 19 and 21 serum concentrations in children and adolescents with normal body weight and obesity and their associations with metabolic parameters. | Socha-Banasiak A et al. | β | 2020 | β |
| Liver-derived FGF21 is essential for full adaptation to ketogenic diet but does not regulate glucose homeostasis. | Watanabe M et al. | β | 2020 | β |
| Liver governs adipose remodelling via extracellular vesicles in response to lipid overload. | Zhao Y et al. | β | 2020 | β |
| Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease? | Gehrke N et al. | β | 2020 | β |
| Mitochondrial uncoupling and longevity - A role for mitokines? | Klaus S et al. | β | 2020 | β |
| MiT/TFE Family of Transcription Factors: An Evolutionary Perspective. | La Spina M et al. | β | 2020 | β |
| Modulatory Effect of Myokines on Reactive Oxygen Species in Ischemia/Reperfusion. | SzabΓ³ MR et al. | β | 2020 | β |
| Myokines as biomarkers of frailty and cardiovascular disease risk in females. | Boreskie KF et al. | β | 2020 | β |
| Myokines: The endocrine coupling of skeletal muscle and bone. | Gomarasca M et al. | β | 2020 | β |
| N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects. | Kanasaki K | β | 2020 | β |
| Obesity medications in development. | Rebello CJ et al. | β | 2020 | β |
| Optimization of Peptide Inhibitors of Ξ²-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21. | Pan J et al. | β | 2020 | β |
| Organokines in disease. | Chung HS et al. | β | 2020 | β |
| Overexpression of fibroblast growth factor-21 (FGF-21) protects mesenchymal stem cells against caspase-dependent apoptosis induced by oxidative stress and inflammation. | Linares GR et al. | β | 2020 | β |
| Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. | Verzijl CRC et al. | β | 2020 | β |
| Potential roles of bone morphogenetic protein-9 in glucose and lipid homeostasis. | Wang Y et al. | β | 2020 | β |
| Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. | Liu Q et al. | β | 2020 | β |
| Proteomic profiles before and during weight loss: Results from randomized trial of dietary intervention. | Figarska SM et al. | β | 2020 | β |
| Recent advances in modulators of circadian rhythms: an update and perspective. | Huang S et al. | β | 2020 | β |
| Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands. | Zhao M et al. | β | 2020 | β |
| Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease. | Tucker B et al. | β | 2020 | β |
| Semantic text mining in early drug discovery for type 2 diabetes. | Hansson LK et al. | β | 2020 | β |
| Serum FGF-21 and FGF-23 in association with gestational diabetes: a longitudinal case-control study. | Mosavat M et al. | β | 2020 | β |
| Surgery-Induced Weight Loss and Changes in Hormonally Active Fibroblast Growth Factors: a Systematic Review and Meta-Analysis. | Hosseinzadeh A et al. | β | 2020 | β |
| Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. | Gilroy CA et al. | β | 2020 | β |
| Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response. | Yang Q et al. | β | 2020 | β |
| Systemic effects of mitochondrial stress. | Bar-Ziv R et al. | β | 2020 | β |
| Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH). | Kim K et al. | β | 2020 | β |
| The effect of hydration status on plasma FGF21 concentrations in humans:Β A subanalysis of a randomised crossover trial. | Carroll HA et al. | β | 2020 | β |
| Therapeutic Effects of Fibroblast Growth Factor-21 on Diabetic Nephropathy and the Possible Mechanism in Type 1 Diabetes Mellitus Mice. | Weng W et al. | β | 2020 | β |
| The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication. | Sponton CH et al. | β | 2020 | β |
| The Role of the Gut Microbiome in Energy Balance With a Focus on the Gut-Adipose Tissue Axis. | Xiao H et al. | β | 2020 | β |
| The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. | Cymbaluk-PΕoska A et al. | β | 2020 | β |
| The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. | Geng L et al. | β | 2020 | β |
| Weight Loss and Concomitant Adipose Autophagy in Methionine-Restricted Obese Mice is Not Dependent on Adiponectin or FGF21. | Cooke D et al. | β | 2020 | β |
| Whole-body and adipose tissue-specific mechanisms underlying the metabolic effects of fibroblast growth factor 21 in the Siberian hamster. | Lewis JE et al. | β | 2020 | β |
| Whole transcriptome analysis and validation of metabolic pathways in subcutaneous adipose tissues during FGF21-induced weight loss in non-human primates. | Murray SA et al. | β | 2020 | β |
| Ξ±Klotho attenuates cardiac hypertrophy and increases myocardial fibroblast growth factor 21 expression in uremic rats. | Suassuna PGA et al. | β | 2020 | β |
| A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21. | Kliewer SA et al. | β | 2019 | β |
| A single combination gene therapy treats multiple age-related diseases. | Davidsohn N et al. | β | 2019 | β |
| Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer. | Kang YE et al. | β | 2019 | β |
| Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis. | Ong KL et al. | β | 2019 | β |
| B-cell translocation gene 2 enhances fibroblast growth factor 21 production by inducing Kruppel-like factor 15. | Kim YD et al. | β | 2019 | β |
| Beige Fat, Adaptive Thermogenesis, and Its Regulation by Exercise and Thyroid Hormone. | Phillips KJ | β | 2019 | β |
| Betulinic acid inhibits high-fat diet-induced obesity and improves energy balance by activating AMPK. | Kim KD et al. | β | 2019 | β |
| Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. | Funcke JB et al. | β | 2019 | β |
| Bilateral Interrelationship of Diabetes and Periodontium. | Badiger AB et al. | β | 2019 | β |
| Carbohydrate Sensing Through the Transcription Factor ChREBP. | Ortega-Prieto P et al. | β | 2019 | β |
| Cardiac myocyte KLF5 regulates body weight via alteration of cardiac FGF21. | Pol CJ et al. | β | 2019 | β |
| Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21. | Marchelek-MyΕliwiec M et al. | β | 2019 | β |
| Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins. | Latko M et al. | β | 2019 | β |
| CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. | Wang K et al. | β | 2019 | β |
| Cytokines and Abnormal Glucose and Lipid Metabolism. | Shi J et al. | β | 2019 | β |
| Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner. | Zhang J et al. | β | 2019 | β |
| Deficiency of fibroblast growth factor 21 aggravates obesity-induced atrophic responses in skeletal muscle. | Kim CS et al. | β | 2019 | β |
| Dietary Sulfur Amino Acid Restriction and the Integrated Stress Response: Mechanistic Insights. | Jonsson WO et al. | β | 2019 | β |
| Effect of exercise intensity on circulating hepatokine concentrations in healthy men. | Willis SA et al. | β | 2019 | β |
| Effects of long-term feeding of rapeseed meal on skeletal muscle transcriptome, production efficiency and meat quality traits in Norwegian Landrace growing-finishing pigs. | Skugor A et al. | β | 2019 | β |
| Effects of Moderate Chronic Food Restriction on the Development of Postprandial Dyslipidemia with Ageing. | FernΓ‘ndez A et al. | β | 2019 | β |
| Emerging Structure-Function Paradigm of Endocrine FGFs in Metabolic Diseases. | Luo Y et al. | β | 2019 | β |
| ER-associated degradation in health and disease - from substrate to organism. | Bhattacharya A et al. | β | 2019 | β |
| Evaluation of a cell model expressing Ξ²Klotho for screening FGF21 analogues. | Guo X et al. | β | 2019 | β |
| Exercise ameliorates the FGF21-adiponectin axis impairment in diet-induced obese mice. | Yang W et al. | β | 2019 | β |
| Exploring the InΒ Vivo Role of the Mitochondrial Calcium Uniporter in Brown Fat Bioenergetics. | Flicker D et al. | β | 2019 | β |
| FGF19 subfamily members: FGF19 and FGF21. | Dolegowska K et al. | β | 2019 | β |
| FGF21 and glycemic control in patients with T1D. | Rosell Rask S et al. | β | 2019 | β |
| FGF21 as Modulator of Metabolism in Health and Disease. | Tezze C et al. | β | 2019 | β |
| FGF21 decreases food intake and body weight in obese GΓΆttingen minipigs. | Christoffersen B et al. | β | 2019 | β |
| FGF21 Signals Protein Status to the Brain and Adaptively Regulates Food Choice and Metabolism. | Hill CM et al. | β | 2019 | β |
| Fibroblast growth factor 21 Ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPKΞ± signaling pathway. | Ying L et al. | β | 2019 | β |
| Fibroblast Growth Factor 21 and Browning of White Adipose Tissue. | Cuevas-Ramos D et al. | β | 2019 | β |
| Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges. | MartΓnez-Garza Γ et al. | β | 2019 | β |
| Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes. | Yafei S et al. | β | 2019 | β |
| Fibroblast Growth Factor-21 Controls Dietary Protein Intake in Male Mice. | Larson KR et al. | β | 2019 | β |
| Fibroblast growth factor 21 deficiency aggravates obesity-induced hypothalamic inflammation and impairs thermogenic response. | Mutsnaini L et al. | β | 2019 | β |
| Fibroblast Growth Factor 21 Drives Dynamics of Local and Systemic Stress Responses in Mitochondrial Myopathy with mtDNA Deletions. | ForsstrΓΆm S et al. | β | 2019 | β |
| Fibroblast Growth Factor 21 Exerts its Anti-inflammatory Effects on Multiple Cell Types of Adipose Tissue in Obesity. | Wang N et al. | β | 2019 | β |
| Fibroblast growth factor 21 improves glucose homeostasis partially via down-regulation of Na<sup>+</sup>-d-glucose cotransporter SGLT1 in the small intestine. | Wang N et al. | β | 2019 | β |
| Fibroblast growth factor 21 in chronic kidney disease. | Anuwatmatee S et al. | β | 2019 | β |
| Fibroblast growth factor 21 in chronic kidney disease. | Suassuna PGA et al. | β | 2019 | β |
| Fibroblast growth factor 21 in non-alcoholic fatty liver disease. | Tucker B et al. | β | 2019 | β |
| Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation. | Refsgaard Holm M et al. | β | 2019 | β |
| Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice. | Zhao C et al. | β | 2019 | β |
| Fibroblast growth factor-21 protects against fibrosis in hypertensive heart disease. | Ferrer-Curriu G et al. | β | 2019 | β |
| Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic Ξ²-cell dysfunction via regulation of AMPK signaling and lipid metabolism. | Xie T et al. | β | 2019 | β |
| Fibroblast growth factor 8b induces uncoupling protein 1 expression in epididymal white preadipocytes. | Westphal S et al. | β | 2019 | β |
| Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of C2C12 and human muscle cells. | Huang J et al. | β | 2019 | β |
| Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. | Struik D et al. | β | 2019 | β |
| Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor Ξ± Modulator (SPPARMΞ±) Pemafibrate. | Sasaki Y et al. | β | 2019 | β |
| Genetic Variants Flanking the <i>FGF21</i> Gene Were Associated with Renal Function in Chinese Patients with Type 2 Diabetes. | Yu W et al. | β | 2019 | β |
| Going Back to the Biology of FGF21: New Insights. | Lewis JE et al. | β | 2019 | β |
| Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease. | Mindur JE et al. | β | 2019 | β |
| Hepatic posttranscriptional network comprised of CCR4-NOT deadenylase and FGF21 maintains systemic metabolic homeostasis. | Morita M et al. | β | 2019 | β |
| Hepatokines-a novel group of exercise factors. | Weigert C et al. | β | 2019 | β |
| Higher serum levels of fibroblast growth factor 21 in old patients with cachexia. | Franz K et al. | β | 2019 | β |
| High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). | Ong KL et al. | β | 2019 | β |
| Identification and validation of common molecular targets of hydroxytyrosol. | LΓ³pez de Las Hazas MC et al. | β | 2019 | β |
| Identification of a crucial amino acid responsible for the loss of specifying FGFR1-KLB affinity of the iodinated FGF21. | Luo W et al. | β | 2019 | β |
| Identification of two microRNA nodes as potential cooperative modulators of liver metabolism. | Hochreuter MY et al. | β | 2019 | β |
| <i>Ishige okamurae</i> Extract Ameliorates the Hyperglycemia and Body Weight Gain of <i>db/db</i> Mice through Regulation of the PI3K/Akt Pathway and Thermogenic Factors by FGF21. | Seo YJ et al. | β | 2019 | β |
| <i>KLB</i> gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese. | Ji F et al. | β | 2019 | β |
| Impact of aging and caloric restriction on fibroblast growth factor 21 signaling in rat white adipose tissue. | Fujii N et al. | β | 2019 | β |
| Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications. | Dianat-Moghadam H et al. | β | 2019 | β |
| Improved FGF21 Sensitivity and Restored FGF21 Signaling Pathway in High-Fat Diet/Streptozotocin-Induced Diabetic Rats After Duodenal-Jejunal Bypass and Sleeve Gastrectomy. | Liu Q et al. | β | 2019 | β |
| Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis. | Wang YS et al. | β | 2019 | β |
| Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. | Furuhashi M et al. | β | 2019 | β |
| In Pursuit of a Biomarker of Weight Gain Susceptibility-Is FGF21 a Candidate? | Redman LM et al. | β | 2019 | β |
| Interaction between the amount of dietary protein and the environmental temperature on the expression of browning markers in adipose tissue of rats. | AlemΓ‘n G et al. | β | 2019 | β |
| Inter-organ communication: a gatekeeper for metabolic health. | Castillo-Armengol J et al. | β | 2019 | β |
| Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications? | Kuro-O M | β | 2019 | β |
| Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure. | Ameka M et al. | β | 2019 | β |
| Low bone mineral density in anorexia nervosa: Treatments and challenges. | Fazeli PK | β | 2019 | β |
| Macronutrients and the Adipose-Liver Axis in Obesity and FattyΒ Liver. | Duwaerts CC et al. | β | 2019 | β |
| Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi. | Xiong X et al. | β | 2019 | β |
| Maresin 1 Regulates Hepatic FGF21 in Diet-Induced Obese Mice and in Cultured Hepatocytes. | MartΓnez-FernΓ‘ndez L et al. | β | 2019 | β |
| Metabolic Determinants of Weight Gain in Humans. | Piaggi P | β | 2019 | β |
| Metabolic implications of organelle-mitochondria communication. | Gordaliza-Alaguero I et al. | β | 2019 | β |
| Metabolic Messengers: fibroblast growth factor 15/19. | Gadaleta RM et al. | β | 2019 | β |
| Metabolic remodeling induced by mitokines in heart failure. | Duan J et al. | β | 2019 | β |
| Metabolic Targets in Nonalcoholic Fatty Liver Disease. | Esler WP et al. | β | 2019 | β |
| Metformin Therapy Aggravates Neurodegenerative Processes in ApoE-/- Mice. | Kuhla A et al. | β | 2019 | β |
| Molecular and Environmental Mechanisms Regulating Puberty Initiation: An Integrated Approach. | Livadas S et al. | β | 2019 | β |
| Molecular Mechanisms Underlying Obesity-Induced Hypothalamic Inflammation and Insulin Resistance: Pivotal Role of Resistin/TLR4 Pathways. | Benomar Y et al. | β | 2019 | β |
| MS-275 induces hepatic FGF21 expression via H3K18ac-mediated CREBH signal. | Zhang Q et al. | β | 2019 | β |
| Mutual promotion of FGF21 and PPARΞ³ attenuates hypoxia-induced pulmonary hypertension. | Cai G et al. | β | 2019 | β |
| Myokines in metabolic homeostasis and diabetes. | Eckel J | β | 2019 | β |
| New Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus. | Catalina MO et al. | β | 2019 | β |
| Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. | Luo Y et al. | β | 2019 | β |
| Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. | Zarei M et al. | β | 2019 | β |
| Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. | Pan Y et al. | β | 2019 | β |
| Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases. | Zhao L et al. | β | 2019 | β |
| Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. | Charles ED et al. | β | 2019 | β |
| Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain. | Scarlett JM et al. | β | 2019 | β |
| Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. | Pennisi G et al. | β | 2019 | β |
| Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes. | Hong ES et al. | β | 2019 | β |
| Protein status modulates the rewarding value of foods and meals to maintain an adequate protein intake. | TomΓ© D et al. | β | 2019 | β |
| Recombinant FGF21 Protects Against Blood-Brain Barrier Leakage Through Nrf2 Upregulation in Type 2 Diabetes Mice. | Yu Z et al. | β | 2019 | β |
| Regulation of metabolic health by essential dietary amino acids. | Green CL et al. | β | 2019 | β |
| Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis. | Anuwatmatee S et al. | β | 2019 | β |
| Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and cardiovascular events: Multi-Ethnic Study of Atherosclerosis. | Ong KL et al. | β | 2019 | β |
| Role of exercise-induced hepatokines in metabolic disorders. | Ennequin G et al. | β | 2019 | β |
| Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini-review. | Yuan D et al. | β | 2019 | β |
| Serum Fibroblast Growth Factor 21 Levels Are Positively Associated with Metabolic Syndrome in Patients with Type 2 Diabetes. | Gao RY et al. | β | 2019 | β |
| Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage. | Bande AR et al. | β | 2019 | β |
| Sex Differences in Liver, Adipose Tissue, and Muscle Transcriptional Response to Fasting and Refeeding in Mice. | Bazhan N et al. | β | 2019 | β |
| Sirt6 deletion in hepatocytes increases insulin sensitivity of female mice by enhancing ERΞ± expression. | Tang C et al. | β | 2019 | β |
| Tanycytes Regulate Lipid Homeostasis by Sensing Free Fatty Acids and Signaling to Key Hypothalamic Neuronal Populations via FGF21 Secretion. | Geller S et al. | β | 2019 | β |
| The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis. | Antonellis PJ et al. | β | 2019 | β |
| The endocrine function of adipose tissues in health and cardiometabolic disease. | Scheja L et al. | β | 2019 | β |
| The FGF metabolic axis. | Li X | β | 2019 | β |
| The influence of skeletal muscle on appetite regulation. | Grannell A et al. | β | 2019 | β |
| The Klotho proteins in health and disease. | Kuro-O M | β | 2019 | β |
| The Level of FGF 21 as a New Risk Factor for the Occurrence of Cardiometabolic Disorders amongst the Psoriatic Patients. | Kiluk P et al. | β | 2019 | β |
| Therapeutic Approaches to Alzheimer's Type of Dementia: A Focus on FGF21 Mediated Neuroprotection. | Taliyan R et al. | β | 2019 | β |
| Thyroid-Hormone-Induced Browning of White Adipose Tissue Does Not Contribute to Thermogenesis and Glucose Consumption. | Johann K et al. | β | 2019 | β |
| YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. | Wang L et al. | β | 2019 | β |
| Ξ²klotho is essential for the anti-endothelial mesenchymal transition effects of N-acetyl-seryl-aspartyl-lysyl-proline. | Gao R et al. | β | 2019 | β |
| 24-h severe energy restriction impairs postprandial glycaemic control in young, lean males. | Clayton DJ et al. | β | 2018 | β |
| A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity. | Shi SY et al. | β | 2018 | β |
| A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. | Frayling TM et al. | β | 2018 | β |
| Activation of Nrf2 signaling by natural products-can it alleviate diabetes? | Matzinger M et al. | β | 2018 | β |
| Adiposity Is a Key Correlate of Circulating Fibroblast Growth Factor-21 Levels in African Males with or without Type 2 Diabetes Mellitus. | Mashili FL et al. | β | 2018 | β |
| Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. | Villarroya J et al. | β | 2018 | β |
| A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity. | Kitada M et al. | β | 2018 | β |
| An implication of Klotho-related molecules in different smoking-related health outcomes between men and women. | Nakanishi K et al. | β | 2018 | β |
| An Integrated View of Immunometabolism. | Lee YS et al. | β | 2018 | β |
| A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents. | El Sagheer GM et al. | β | 2018 | β |
| A systematic dissection of sequence elements determining Ξ²-Klotho and FGF interaction and signaling. | Shi SY et al. | β | 2018 | β |
| Automated assessment of steatosis in murine fatty liver. | Sethunath D et al. | β | 2018 | β |
| A Wars2 Mutant Mouse Model Displays OXPHOS Deficiencies and Activation of Tissue-Specific Stress Response Pathways. | Agnew T et al. | β | 2018 | β |
| Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. | Sun Y et al. | β | 2018 | β |
| Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77. | Zhou F et al. | β | 2018 | β |
| BMP2/Smad signaling pathway is involved in the inhibition function of fibroblast growth factor 21 on vascular calcification. | Liu X et al. | β | 2018 | β |
| Changes in plasma concentrations and mRNA expression of hepatokines fetuin A, fetuin B and FGF21 in physiological pregnancy and gestational diabetes mellitus. | Ε imjΓ‘k P et al. | β | 2018 | β |
| Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. | Lovric A et al. | β | 2018 | β |
| Characterization of fibroblast growth factor 1 in obese children and adolescents | Wang A et al. | β | 2018 | β |
| Chemical genetic-based phenotypic screen reveals novel regulators of gluconeogenesis in human primary hepatocytes. | Zou H et al. | β | 2018 | β |
| Chip-based high resolution tandem mass spectrometric determination of fibroblast growth factor-chondroitin sulfate disaccharides noncovalent interaction. | Robu AC et al. | β | 2018 | β |
| Cholic Acid Supplementation of a High-Fat Obesogenic Diet Suppresses Hepatic Triacylglycerol Accumulation in Mice via a Fibroblast Growth Factor 21-Dependent Mechanism. | Ippagunta SM et al. | β | 2018 | β |
| Circulating fibroblast growth factor 21 is reduced, whereas its production is increased in a fat depot-specific manner in cold-acclimated rats. | Sepa-Kishi DM et al. | β | 2018 | β |
| Control of (pre)-analytical aspects in immunoassay measurements of metabolic hormones in rodents. | Bielohuby M et al. | β | 2018 | β |
| Curcumin and dietary polyphenol research: beyond drug discovery. | Jin TR | β | 2018 | β |
| Cytochrome P450s and Alcoholic Liver Disease. | Lu Y et al. | β | 2018 | β |
| Deficiency in interleukin-18 promotes differentiation of brown adipose tissue resulting in fat accumulation despite dyslipidemia. | Yamanishi K et al. | β | 2018 | β |
| Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. | Singhal G et al. | β | 2018 | β |
| Defining "FGF21 Resistance" during obesity: Controversy, criteria and unresolved questions. | Markan KR | β | 2018 | β |
| Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance. | Maida A et al. | β | 2018 | β |
| Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms. | TreviΓ±o-Villarreal JH et al. | β | 2018 | β |
| Differential receptor selectivity of the FGF15/FGF19 orthologues determines distinct metabolic activities in <i>db/db</i> mice. | Hansen AMK et al. | β | 2018 | β |
| Divergent Role of Estrogen-Related Receptor Ξ± in Lipid- and Fasting-Induced Hepatic Steatosis in Mice. | B'chir W et al. | β | 2018 | β |
| Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia. | Saint-Laurent C et al. | β | 2018 | β |
| Eccentric exercise increases circulating fibroblast activation protein Ξ± but not bioactive fibroblast growth factor 21 in healthy humans. | Parmar B et al. | β | 2018 | β |
| Effective Food Ingredients for Fatty Liver: Soy Protein Ξ²-Conglycinin and Fish Oil. | Yamazaki T et al. | β | 2018 | β |
| Effects of Anorexia Nervosa on Bone Metabolism. | Fazeli PK et al. | β | 2018 | β |
| Effects of central FGF21 infusion on the hypothalamus-pituitary-thyroid axis and energy metabolism in rats. | Yilmaz U et al. | β | 2018 | β |
| Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. | Xu L et al. | β | 2018 | β |
| Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice. | Jiang Y et al. | β | 2018 | β |
| Enhanced Hepatic PPARΞ± Activity Links GLUT8 Deficiency to Augmented Peripheral Fasting Responses in Male Mice. | Mayer AL et al. | β | 2018 | β |
| Enteric Microbiotaβ»Gutβ»Brain Axis from the Perspective of Nuclear Receptors. | Duszka K et al. | β | 2018 | β |
| Epigenetic modulation of Fgf21 in the perinatal mouse liver ameliorates diet-induced obesity in adulthood. | Yuan X et al. | β | 2018 | β |
| Fasting decreases plasma FGF21 in obese subjects and the expression of FGF21 receptors in adipose tissue in both lean and obese subjects | Nygaard EB et al. | β | 2018 | β |
| FGF21 acts as a negative regulator of bile acid synthesis. | Chen MM et al. | β | 2018 | β |
| FGF21 Alleviates Hepatic Endoplasmic Reticulum Stress under Physiological Conditions. | Maruyama R et al. | β | 2018 | β |
| FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats. | Sa-Nguanmoo P et al. | β | 2018 | β |
| FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro. | Zhang S et al. | β | 2018 | β |
| FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys. | Andersen B et al. | β | 2018 | β |
| FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation. | Li JY et al. | β | 2018 | β |
| FGF21 gene therapy as treatment for obesity and insulin resistance. | Jimenez V et al. | β | 2018 | β |
| FGF21 increases water intake, urine output and blood pressure in rats. | Turner T et al. | β | 2018 | β |
| FGF-21 Plays a Crucial Role in the Glucose Uptake of Activated Monocytes. | Wang N et al. | β | 2018 | β |
| FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. | Pan X et al. | β | 2018 | β |
| FGF21 Protects the Blood-Brain Barrier by Upregulating PPARΞ³ via FGFR1/Ξ²-klotho after Traumatic Brain Injury. | Chen J et al. | β | 2018 | β |
| FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. | Manoli I et al. | β | 2018 | β |
| Fibroblast growth factor 21, adiposity, and macronutrient balance in a healthy, pregnant population with overweight and obesity. | Sutton EF et al. | β | 2018 | β |
| Fibroblast growth factor 21 attenuates hypoxia-induced pulmonary hypertension by upregulating PPARΞ³ expression and suppressing inflammatory cytokine levels. | Liu J et al. | β | 2018 | β |
| Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis. | BonDurant LD et al. | β | 2018 | β |
| Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor Ξ³ coactivator-1Ξ±-deficient mice. | Fletcher JA et al. | β | 2018 | β |
| Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. | Li H et al. | β | 2018 | β |
| Fibroblast growth factor 21 induces lipolysis more efficiently than it suppresses lipogenesis in goat adipocytes. | Zhang Y et al. | β | 2018 | β |
| Fibroblast growth factor 21 inhibits atherosclerosis in apoE-/- mice by ameliorating Fas-mediated apoptosis. | Yan X et al. | β | 2018 | β |
| Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages. | Wang N et al. | β | 2018 | β |
| Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption. | Li S et al. | β | 2018 | β |
| Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. | Tassi E et al. | β | 2018 | β |
| Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action. | Gilroy CA et al. | β | 2018 | β |
| Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21. | Kim T et al. | β | 2018 | β |
| Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. | Weng Y et al. | β | 2018 | β |
| Harnessing the Integrated Stress Response to Counteract Metabolic Disease. | Henkel AS | β | 2018 | β |
| Hepatic Sel1L-Hrd1 ER-associated degradation (ERAD) manages FGF21 levels and systemic metabolism via CREBH. | Bhattacharya A et al. | β | 2018 | β |
| Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21. | Sawicki KT et al. | β | 2018 | β |
| Hepatokine Ξ±1-Microglobulin Signaling Exacerbates Inflammation and Disturbs Fibrotic Repair in Mouse Myocardial Infarction. | Hakuno D et al. | β | 2018 | β |
| High expression of fibroblast growth factor-21 in liposarcoma patients indicated better prognosis and less recurrence. | Lou Y et al. | β | 2018 | β |
| Highly selective and sensitive measurement of active forms of FGF21 using novel immunocapture enrichment with LC-MS/MS. | Zhao Y et al. | β | 2018 | β |
| Homeostatic sensing of dietary protein restriction: A case for FGF21. | Hill CM et al. | β | 2018 | β |
| Human fibroblast growth factor-21 serves as a predictor and prognostic factor in patients with hepatitis B cirrhosis combined with adrenal insufficiency. | Zhang J et al. | β | 2018 | β |
| Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population. | Reinehr T et al. | β | 2018 | β |
| Inhibiting the integrated stress response pathway prevents aberrant chondrocyte differentiation thereby alleviating chondrodysplasia. | Wang C et al. | β | 2018 | β |
| Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy. | Wei W et al. | β | 2018 | β |
| Intestinal de novo phosphatidylcholine synthesis is required for dietary lipid absorption and metabolic homeostasis. | Kennelly JP et al. | β | 2018 | β |
| Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease. | Miyazaki Y et al. | β | 2018 | β |
| LY2405319, an analog of fibroblast growth factor 21 ameliorates Ξ±-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice. | Le CT et al. | β | 2018 | β |
| Mechanisms of Insulin Action and Insulin Resistance. | Petersen MC et al. | β | 2018 | β |
| Mediterranean Tomato-Based Sofrito Sauce Improves Fibroblast Growth Factor 21 (FGF21) Signaling in White Adipose Tissue of Obese ZUCKER Rats. | Sandoval V et al. | β | 2018 | β |
| Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation. | Kim EK et al. | β | 2018 | β |
| Mitochondrial diseases: the contribution of organelle stress responses to pathology. | Suomalainen A et al. | β | 2018 | β |
| Mitophagy Directs Muscle-Adipose Crosstalk to Alleviate Dietary Obesity. | Fu T et al. | β | 2018 | β |
| Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. | Agrawal A et al. | β | 2018 | β |
| Monoclonal antibody targeting of fibroblast growth factor receptor 1c causes cardiac valvulopathy in rats. | Buss N et al. | β | 2018 | β |
| Muscle-Adipose Tissue Cross Talk. | Stanford KI et al. | β | 2018 | β |
| Negative association between serum aryl hydrocarbon receptor concentrations and Ξ²-cell function in patients with no history of diabetes undergoing coronary angiography. | Wang JS et al. | β | 2018 | β |
| Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. | Zapata L et al. | β | 2018 | β |
| New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases. | Win S et al. | β | 2018 | β |
| Parsing the Potential Neuroendocrine Actions of FGF21 in Primates. | Gillum MP | β | 2018 | β |
| Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. | Kim KH et al. | β | 2018 | β |
| Perilipin-2 deletion promotes carbohydrate-mediated browning of white adipose tissue at ambient temperature. | Libby AE et al. | β | 2018 | β |
| Pharmacokinetics, tissue distribution, and excretion of FGF-21 following subcutaneous administration in rats. | He Y et al. | β | 2018 | β |
| Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases. | Leal LG et al. | β | 2018 | β |
| Plasma Levels of Myonectin But Not Myostatin or Fibroblast-Derived Growth Factor 21 Are Associated with Insulin Resistance in Adult Humans without Diabetes Mellitus. | Toloza FJK et al. | β | 2018 | β |
| Preemptive Activation of the Integrated Stress Response Protects Mice From Diet-Induced Obesity and Insulin Resistance by Fibroblast Growth Factor 21 Induction. | Xu X et al. | β | 2018 | β |
| Protection Effect of Exogenous Fibroblast Growth Factor 21 on the Kidney Injury in Vascular Calcification Rats. | Shi YC et al. | β | 2018 | β |
| Role of brown adipose tissue in metabolic syndrome, aging, and cancer cachexia. | Dong M et al. | β | 2018 | β |
| Sensing and signaling mechanisms linking dietary methionine restriction to the behavioral and physiological components of the response. | Forney LA et al. | β | 2018 | β |
| Serum fetuin-B is positively associated with intrahepatic triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A cross-sectional study. | Wang D et al. | β | 2018 | β |
| Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study. | Choi JR et al. | β | 2018 | β |
| Serum Levels of FGF21 and Prediction of Cardiovascular Events. | Luo Y et al. | β | 2018 | β |
| Sex differences in the development of hepatic steatosis in cafeteria diet-induced obesity in young mice. | Gasparin FRS et al. | β | 2018 | β |
| Skeletal muscle mitochondrial remodeling in exercise and diseases. | Gan Z et al. | β | 2018 | β |
| The dark side of browning. | Tamucci KA et al. | β | 2018 | β |
| The IRE1Ξ±-XBP1s pathway promotes insulin-stimulated glucose uptake in adipocytes by increasing PPARΞ³ activity. | Cho YM et al. | β | 2018 | β |
| The Peroxisome Proliferator-Activated Receptor Ξ± (PPARΞ±) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice. | Araki M et al. | β | 2018 | β |
| Therapeutic effects of fibroblast growth factorβ21 against atherosclerosis via the NFβΞΊB pathway. | Zhang Y et al. | β | 2018 | β |
| The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. | Hui TH et al. | β | 2018 | β |
| The role of FGF21 in type 1 diabetes and its complications. | Zhang J et al. | β | 2018 | β |
| A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. | Fisher FM et al. | β | 2017 | β |
| Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis. | Kim JY et al. | β | 2017 | β |
| Activation of GR but not PXR by dexamethasone attenuated acetaminophen hepatotoxicities via Fgf21 induction. | Vispute SG et al. | β | 2017 | β |
| Adipose angiotensin II type 1 receptor-associated protein ameliorates metabolic disorders via promoting adipose tissue adipogenesis and browning. | Luo C et al. | β | 2017 | β |
| Adipose tissue autophagy and homeostasis in alcohol-induced liver injury. | Li Y et al. | β | 2017 | β |
| Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: The role of the PPARΞ±-FGF21 axis. | Chen X et al. | β | 2017 | β |
| Alterations in 3-Hydroxyisobutyrate and FGF21 Metabolism Are Associated With Protein Ingestion-Induced Insulin Resistance. | Harris LLS et al. | β | 2017 | β |
| An integrative analysis of tissue-specific transcriptomic and metabolomic responses to short-term dietary methionine restriction in mice. | Ghosh S et al. | β | 2017 | β |
| A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward Ξ²-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys. | Stanislaus S et al. | β | 2017 | β |
| Antibody-Mediated Targeting of the FGFR1c Isoform Increases Glucose Uptake in White and Brown Adipose Tissue in Male Mice. | Lewis JE et al. | β | 2017 | β |
| Anti-inflammatory effects of exercise training in adipose tissue do not require FGF21. | Porter JW et al. | β | 2017 | β |
| Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. | Kohara M et al. | β | 2017 | β |
| Associations Among Cardio-Ankle Vascular Index, Carotid Intima-Media Thickness, and Fibroblast Growth Factor-21 Levels in Kidney Transplant Patients. | Trakarnvanich T et al. | β | 2017 | β |
| Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. | Ong KL et al. | β | 2017 | β |
| Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action. | Zhang J et al. | β | 2017 | β |
| Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. | Lundsgaard AM et al. | β | 2017 | β |
| Comparative microarray analyses of mono(2-ethylhexyl)phthalate impacts on fat cell bioenergetics and adipokine network. | Chiang HC et al. | β | 2017 | β |
| Crosstalk between adipokines and myokines in fat browning. | RodrΓguez A et al. | β | 2017 | β |
| Decreased levels of Fibroblast Growth Factor 21 are correlated with improved hypoglycemia in patients with insulinoma. | Li X et al. | β | 2017 | β |
| Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes. | Kruse R et al. | β | 2017 | β |
| Endocrine and autocrine/paracrine modulators of brown adipose tissue mass and activity as novel therapeutic strategies against obesity and type 2 diabetes. | Scheideler M et al. | β | 2017 | β |
| Estradiol Regulation of Brown Adipose Tissue Thermogenesis. | GonzΓ‘lez-GarcΓa I et al. | β | 2017 | β |
| Fasting-induced hormonal regulation of lysosomal function. | Chen L et al. | β | 2017 | β |
| FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. | GΓ³mez-Ambrosi J et al. | β | 2017 | β |
| FGF19, FGF21, and an FGFR1/Ξ²-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. | Lan T et al. | β | 2017 | β |
| FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in mice. | Wu F et al. | β | 2017 | β |
| FGF21 deficiency is associated with childhood obesity, insulin resistance and hypoadiponectinaemia: The BCAMS Study. | Li G et al. | β | 2017 | β |
| FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis. | Mottillo EP et al. | β | 2017 | β |
| FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response. | Yu D et al. | β | 2017 | β |
| FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. | Laeger T et al. | β | 2017 | β |
| FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans. | SΓΈberg S et al. | β | 2017 | β |
| FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARΞ± and PPARΞ³ Agonists. | Li X et al. | β | 2017 | β |
| Fgf21 is required for cardiac remodeling in pregnancy. | Redondo-Angulo I et al. | β | 2017 | β |
| FGF21 Mediates the Thermogenic and Insulin-Sensitizing Effects of Dietary Methionine Restriction but Not Its Effects on Hepatic Lipid Metabolism. | Wanders D et al. | β | 2017 | β |
| FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. | Sonoda J et al. | β | 2017 | β |
| FGF21 regulates melanogenesis in alpaca melanocytes via ERK1/2-mediated MITF downregulation. | Wang R et al. | β | 2017 | β |
| Fgf21 regulates T-cell development in the neonatal and juvenile thymus. | Nakayama Y et al. | β | 2017 | β |
| FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue. | Markan KR et al. | β | 2017 | β |
| Fibroblast growth factor 21 and its novel association with oxidative stress. | GΓ³mez-SΓ‘mano MΓ et al. | β | 2017 | β |
| Fibroblast growth factor 21: a regulator of metabolic disease and health span. | Xie T et al. | β | 2017 | β |
| Fibroblast growth factor 21, assisted by elevated glucose, activates paraventricular nucleus NUCB2/Nesfatin-1 neurons to produce satiety under fed states. | Santoso P et al. | β | 2017 | β |
| Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. | Braun LR et al. | β | 2017 | β |
| Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. | Desai BN et al. | β | 2017 | β |
| Fibroblast Growth Factor 21-Metabolic Role in Mice and Men. | Staiger H et al. | β | 2017 | β |
| Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis. | Kwok KHM et al. | β | 2017 | β |
| Fibroblast growth factor 21 night watch: advances and uncertainties in the field. | Kharitonenkov A et al. | β | 2017 | β |
| Fibroblast Growth Factor 21 Promotes C2C12 Cells Myogenic Differentiation by Enhancing Cell Cycle Exit. | Liu X et al. | β | 2017 | β |
| Fibroblast growth factor 21 protects rat cardiomyocytes from endoplasmic reticulum stress by promoting the fibroblast growth factor receptor 1-extracellular signalβregulated kinase 1/2 signaling pathway. | Liang P et al. | β | 2017 | β |
| Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats. | Charoenphandhu N et al. | β | 2017 | β |
| Fibroblast growth factor 21 reverses suppression of adiponectin expression via inhibiting endoplasmic reticulum stress in adipose tissue of obese mice. | Guo Q et al. | β | 2017 | β |
| From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. | Caputo T et al. | β | 2017 | β |
| Glycemic control and adipokines after periodontal therapy in patients with Type 2 diabetes and chronic periodontitis. | Wang S et al. | β | 2017 | β |
| Hepatic, adipocyte, enteric and pancreatic hormones: response to dietary macronutrient composition and relationship with metabolism. | Hron BM et al. | β | 2017 | β |
| Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. | Meex RCR et al. | β | 2017 | β |
| High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients. | Gallego-Escuredo JM et al. | β | 2017 | β |
| Host-microbiome interactions: the aryl hydrocarbon receptor and the central nervous system. | Lee HU et al. | β | 2017 | β |
| How does obesity lead to insulin resistance? | Choi CHJ et al. | β | 2017 | β |
| Human ADMC-Derived Adipocyte Thermogenic Capacity Is Regulated by IL-4 Receptor. | Lizcano F et al. | β | 2017 | β |
| Hypothalamic-Pituitary Axis Regulates Hydrogen Sulfide Production. | Hine C et al. | β | 2017 | β |
| Identification of Sp1 as a Transcription Activator to Regulate Fibroblast Growth Factor 21 Gene Expression. | Chen S et al. | β | 2017 | β |
| Impact of FGF21 on glycemic control. | Strowski MZ | β | 2017 | β |
| Impact of Fibroblast Growth Factors 19 and 21 in Bariatric Metabolism. | Patton A et al. | β | 2017 | β |
| Increased glucose-stimulated FGF21 response to oral glucose in obese nondiabetic subjects after Roux-en-Y gastric bypass. | Vienberg SG et al. | β | 2017 | β |
| Induction of fibroblast growth factor 21 does not require activation of the hepatic X-box binding protein 1 in mice. | Olivares S et al. | β | 2017 | β |
| Induction of lipogenesis in white fat during cold exposure in mice: link to lean phenotype. | Flachs P et al. | β | 2017 | β |
| Influence of anaerobic and aerobic exercise on age-related pathways in skeletal muscle. | Navas-Enamorado I et al. | β | 2017 | β |
| Insulin Resistance and Mitochondrial Dysfunction. | Gonzalez-Franquesa A et al. | β | 2017 | β |
| Level of dietary energy and 2,4-thiazolidinedione alter molecular and systemic biomarkers of inflammation and liver function in Holstein cows. | Hosseini A et al. | β | 2017 | β |
| Lifestyle precision medicine: the next generation in type 2 diabetes prevention? | Mutie PM et al. | β | 2017 | β |
| Long Distance Metabolic Regulation through Adipose-Derived Circulating Exosomal miRNAs: A Trail for RNA-Based Therapies? | Fatima F et al. | β | 2017 | β |
| Long-Term Cold Adaptation Does Not Require FGF21 or UCP1. | Keipert S et al. | β | 2017 | β |
| Low protein-induced increases in FGF21 drive UCP1-dependent metabolic but not thermoregulatory endpoints. | Hill CM et al. | β | 2017 | β |
| LPS infusion suppresses serum FGF21 levels in healthy adult volunteers. | Lauritzen ES et al. | β | 2017 | β |
| Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues. | Lin X et al. | β | 2017 | β |
| Modifying the Dietary Carbohydrate-to-Protein Ratio Alters the Postprandial Macronutrient Oxidation Pattern in Liver of AMPK-Deficient Mice. | Chalvon-Demersay T et al. | β | 2017 | β |
| Muscle Sympathetic Nerve Activity Is Associated with Liver Insulin Sensitivity in Obese Non-Diabetic Men. | Chen DL et al. | β | 2017 | β |
| N-3 polyunsaturated fatty acids increase hepatic fibroblast growth factor 21 sensitivity via a PPAR-Ξ³-Ξ²-klotho pathway. | Yang W et al. | β | 2017 | β |
| Neohesperidin Exerts Lipid-Regulating Effects in vitro and in vivo via Fibroblast Growth Factor 21 and AMP-Activated Protein Kinase/Sirtuin Type 1/Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1Ξ± Signaling Axis. | Wu H et al. | β | 2017 | β |
| New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic Ξ²-Cells and Hepatocytes. | Lee WY | β | 2017 | β |
| Nuclear factor E2-related factor 2 knockdown enhances glucose uptake and alters glucose metabolism in AML12 hepatocytes. | Yuan X et al. | β | 2017 | β |
| Peripherally derived FGF21 promotes remyelination in the central nervous system. | Kuroda M et al. | β | 2017 | β |
| Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. | Ye X et al. | β | 2017 | β |
| Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice. | Zhao L et al. | β | 2017 | β |
| Prenatal PPARΞ± activation by clofibrate increases subcutaneous fat browning in male C57BL/6J mice fed a high-fat diet during adulthood. | Chen SH et al. | β | 2017 | β |
| Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein. | Nguyen AN et al. | β | 2017 | β |
| Proteomics in Hypothermia as Adjunctive Therapy in Patients with ST-Segment Elevation Myocardial Infarction: A CHILL-MI Substudy. | Mohammad MA et al. | β | 2017 | β |
| Reduced adiposity attenuates FGF21 mediated metabolic improvements in the Siberian hamster. | Lewis JE et al. | β | 2017 | β |
| Reduction in serum fibroblast growth factor-21 after gastric bypass is related to changes in hepatic fat content. | Fjeldborg K et al. | β | 2017 | β |
| Repletion of branched chain amino acids reverses mTORC1 signaling but not improved metabolism during dietary protein dilution. | Maida A et al. | β | 2017 | β |
| Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. | Luo Y et al. | β | 2017 | β |
| Serum FGF21 Levels in Obese Korean Children and Adolescents. | Baek J et al. | β | 2017 | β |
| Serum FGF21 Levels in Obese Korean Children and Adolescents (J Obes Metab Syndr 2017;26:204-9). | Kim JH | β | 2017 | β |
| Sex-specific association between fibroblast growth factor 21 and type 2 diabetes: a nested case-control study in Singapore Chinese men and women. | Wang Y et al. | β | 2017 | β |
| SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. | Xu L et al. | β | 2017 | β |
| Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. | Wang C et al. | β | 2017 | β |
| Targeting nuclear receptors for the treatment of fatty liver disease. | Tanaka N et al. | β | 2017 | β |
| The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. | Akyol M et al. | β | 2017 | β |
| The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity. | Huang Z et al. | β | 2017 | β |
| The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans. | Ter Horst KW et al. | β | 2017 | β |
| The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-Ξ± agonist-induced amelioration of metabolic disorders in obese mice. | Goto T et al. | β | 2017 | β |
| The New Biology and Pharmacology of Glucagon. | MΓΌller TD et al. | β | 2017 | β |
| The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension. | Huang Z et al. | β | 2017 | β |
| The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes. | Izaguirre M et al. | β | 2017 | β |
| The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus. | Jung CH et al. | β | 2017 | β |
| Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. | Huang Z et al. | β | 2017 | β |
| Ξ±1-Adrenergic receptor downregulates hepatic FGF21 production and circulating FGF21 levels in mice. | Nonogaki K et al. | β | 2017 | β |
| Ξ²-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. | Somm E et al. | β | 2017 | β |
| Acute endurance exercise lowers serum fibroblast growth factor 21 levels in Japanese men. | Taniguchi H et al. | β | 2016 | β |
| Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation. | Tanimura Y et al. | β | 2016 | β |
| Adipokine Pattern After Bariatric Surgery: Beyond the Weight Loss. | Adami GF et al. | β | 2016 | β |
| Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. | Stern JH et al. | β | 2016 | β |
| A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. | Woolsey SJ et al. | β | 2016 | β |
| A High Phosphorus Diet Affects Lipid Metabolism in Rat Liver: A DNA Microarray Analysis. | Chun S et al. | β | 2016 | β |
| A High-Throughput Targeted Proteomic Approach for Comprehensive Profiling of Methylglyoxal-Induced Perturbations of the Human Kinome. | Miao W et al. | β | 2016 | β |
| An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. | Lee JH et al. | β | 2016 | β |
| Anti-human fibroblast growth factor-21 monoclonal antibody preparation, characterization and analysis of <i>in vitro</i> bioactivity. | Ding L et al. | β | 2016 | β |
| Assessment of growth and metabolism characteristics in offspring of dehydroepiandrosterone-induced polycystic ovary syndrome adults. | Huang Y et al. | β | 2016 | β |
| Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients. | Bagheri L et al. | β | 2016 | β |
| A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity. | Kitada M et al. | β | 2016 | β |
| BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity. | Kim S et al. | β | 2016 | β |
| Brown and Beige Adipose Tissue: Therapy for Obesity and Its Comorbidities? | Mulya A et al. | β | 2016 | β |
| Canine Fibroblast Growth Factor 21 Ameliorates Hyperglycemia Associated with Inhibiting Hepatic Gluconeogenesis and Improving Pancreatic Beta-Cell Survival in Diabetic Mice and Dogs. | Xu P et al. | β | 2016 | β |
| Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer. | Knott ME et al. | β | 2016 | β |
| Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction. | Chou RH et al. | β | 2016 | β |
| CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis. | Park JG et al. | β | 2016 | β |
| Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease. | Corsetti G et al. | β | 2016 | β |
| Discovery of an artificial peptide agonist to the fibroblast growth factor receptor 1c/Ξ²Klotho complex from random peptide T7 phage display. | Sakamoto K et al. | β | 2016 | β |
| Efficacy of a combination of high and low dosage of PEGylated FGF-21 in treatment of diabetes in db/db mice. | Xu P et al. | β | 2016 | β |
| Elevated Serum Fibroblast Growth Factor 21 in Humans with Acute Pancreatitis. | Shenoy VK et al. | β | 2016 | β |
| Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. | Hu Y et al. | β | 2016 | β |
| FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. | Zhu S et al. | β | 2016 | β |
| FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency. | Dollet L et al. | β | 2016 | β |
| FGF21 Is Associated with Acanthosis Nigricans in Obese Patients. | Huang Y et al. | β | 2016 | β |
| Fibroblast activation protein (FAP) as a novel metabolic target. | SΓ‘nchez-Garrido MA et al. | β | 2016 | β |
| Fibroblast growth factor 21 - a key player in cardiovascular disorders? | Lenart-LipiΕska M et al. | β | 2016 | β |
| Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus. | So WY et al. | β | 2016 | β |
| Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents. | Khan FH et al. | β | 2016 | β |
| Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. | Liu Y et al. | β | 2016 | β |
| Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-ΞΊB signaling pathway. | Yu Y et al. | β | 2016 | β |
| Fibroblast growth factor 21, fibroblast growth factor receptor 1, and Ξ²-Klotho expression in bovine growth hormone transgenic and growth hormone receptor knockout mice. | Brooks NE et al. | β | 2016 | β |
| Fibroblast growth factor 21 has no direct role in regulating fertility in female mice. | Singhal G et al. | β | 2016 | β |
| Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. | Gong Q et al. | β | 2016 | β |
| Fibroblast growth factor 21 induction by activating transcription factor 4 is regulated through three amino acid response elements in its promoter region. | Maruyama R et al. | β | 2016 | β |
| Fibroblast growth factor 21 is required for beneficial effects of exercise during chronic high-fat feeding. | Loyd C et al. | β | 2016 | β |
| Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting. | Antonellis PJ et al. | β | 2016 | β |
| Fibroblast growth factor 21 signaling: The liver in focus. | Mahlapuu M et al. | β | 2016 | β |
| Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity. | Yin J et al. | β | 2016 | β |
| Genetic insights into the mechanisms of Fgf signaling. | Brewer JR et al. | β | 2016 | β |
| Hepatic Fgf21 Expression Is Repressed after Simvastatin Treatment in Mice. | Ziros P et al. | β | 2016 | β |
| Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle. | Vandanmagsar B et al. | β | 2016 | β |
| iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy. | Lynch L et al. | β | 2016 | β |
| Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. | Liu X et al. | β | 2016 | β |
| Lactate as a Signaling Molecule That Regulates Exercise-Induced Adaptations. | Nalbandian M et al. | β | 2016 | β |
| Lipodystrophy HIV-related and FGF21: A new marker to follow the progression of lipodystrophy? | Benedini S et al. | β | 2016 | β |
| MECHANISMS IN ENDOCRINOLOGY: Brown adipose tissue in humans: regulation and metabolic significance. | Thuzar M et al. | β | 2016 | β |
| Metabolic effects of basic fibroblast growth factor in streptozotocin-induced diabetic rats: A <sup>1</sup>H NMR-based metabolomics investigation. | Lin X et al. | β | 2016 | β |
| miR-149 controls non-alcoholic fatty liver by targeting FGF-21. | Xiao J et al. | β | 2016 | β |
| Modulation of energy balance by fibroblast growth factor 21. | Cuevas-Ramos D et al. | β | 2016 | β |
| Molecular hydrogen stimulates the gene expression of transcriptional coactivator PGC-1Ξ± to enhance fatty acid metabolism. | Kamimura N et al. | β | 2016 | β |
| mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. | Minard AY et al. | β | 2016 | β |
| mTORC1 is Required for Brown Adipose Tissue Recruitment and Metabolic Adaptation to Cold. | LabbΓ© SM et al. | β | 2016 | β |
| Novel Molecules Regulating Energy Homeostasis: Physiology and Regulation by Macronutrient Intake and Weight Loss. | Gavrieli A et al. | β | 2016 | β |
| Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds. | PΓ©rez-MartΓ A et al. | β | 2016 | β |
| PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates. | Thompson WC et al. | β | 2016 | β |
| Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases. | Cheng P et al. | β | 2016 | β |
| Pilot-scale production and characterization of PEGylated human FGF-21 analog. | Ye X et al. | β | 2016 | β |
| Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors. | Schumacher JD et al. | β | 2016 | β |
| Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? | Targher G et al. | β | 2016 | β |
| Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice. | Morrison CD et al. | β | 2016 | β |
| Serum concentrations of fibroblast growth factor 21 are elevated in patients with congenital or acquired lipodystrophy. | Miehle K et al. | β | 2016 | β |
| SERUM LEVELS OF FIBROBLAST GROWTH FACTOR 21 IN TYPE 2 DIABETIC PATIENTS. | Panahi Y et al. | β | 2016 | β |
| The ever-expanding myokinome: discovery challenges and therapeutic implications. | Whitham M et al. | β | 2016 | β |
| The FGF21 Receptor Signaling Complex: KlothoΞ², FGFR1c, and Other Regulatory Interactions. | Kilkenny DM et al. | β | 2016 | β |
| The Multifaceted Roles of Adipose Tissue-Therapeutic Targets for Diabetes and Beyond: The 2015 Banting Lecture. | Scherer PE | β | 2016 | β |
| The Orphan Nuclear Receptor ERRΞ³ Regulates Hepatic CB1 Receptor-Mediated Fibroblast Growth Factor 21 Gene Expression. | Jung YS et al. | β | 2016 | β |
| The regulation of FGF21 gene expression by metabolic factors and nutrients. | Erickson A et al. | β | 2016 | β |
| The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis. | Herman MA et al. | β | 2016 | β |
| Treatment with FGFR2-IIIc monoclonal antibody suppresses weight gain and adiposity in KKA<sup>y</sup> mice. | Nonogaki K et al. | β | 2016 | β |